$425.28
+5.90 (+1.41%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AMGN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 456 interventional · 44 observational · 261 with posted results
Held by 18 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +13 more) · FINRA short interest 5.2 days to cover (settled 2026-07-31) · government filings 180d: 4 congress / 8 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisNCT06072482Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 4 | Recruiting | Drug: Avacopan, Placebo, Standard of Care | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | 300 | 2036-12-31 | in 3,787 d | 2026-08-14 |
| A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisNCT05767047Number of Participants with Adverse EventsOpen-label · Treatment | Phase 3 | Recruiting | Drug: Apremilast | Behçet's Disease, Juvenile Psoriatic Arthritis | 48 | 2036-03-17 | in 3,498 d | 2025-12-01 |
| Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyNCT05909761observationalNumber of newborns with Major Congenital Malformations (MCMs) | — | Recruiting | Drug: UPLIZNA | Neuromyelitis Optica Spectrum Disorder, Pregnancy Related | 60 | 2032-10-31 | in 2,265 d | 2026-01-27 |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsNCT07136012Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs FirstRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Olpasiran, Placebo | Cardiovascular Disease | 11,000 | 2031-10-20 | in 1,888 d | 2026-08-13 |
| A Trial of Inebilizumab in Participants With Autoimmune HepatitisNCT07598825Part 1: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs of Interest at Week 26Randomized · Double-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Inebilizumab, Placebo · Other: Standard of Care | Autoimmune Hepatitis, AIH | 180 | 2031-07-30 | in 1,806 d | 2026-08-14 |
| Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)NCT06898957Number of Participants Experiencing Dose-limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: YL201, Tarlatamab, Durvalumab | Small Cell Lung Cancer | 29 | 2031-06-23 | in 1,769 d | 2026-05-20 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDNCT07222553Maximum Plasma Concentration (Cmax) of InebilizumabOpen-label · Treatment | Phase 2 | Not yet recruiting | Drug: Inebilizumab | Immunoglobulin G4-related Disease | 15 | 2031-06-10 | in 1,756 d | 2026-05-04 |
| Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)NCT07297979Number of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only)Non-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: Xaluritamig | Ewing Sarcoma | 50 | 2030-05-26 | in 1,376 d | 2026-07-16 |
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic LeukaemiaNCT07223190Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: Blinatumomab, Blinatumomab, HyperCVAD | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | 560 | 2030-05-10 | in 1,360 d | 2026-03-04 |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)NCT06117774PFS as Determined by BICRRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Tarlatamab, Placebo | Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | 404 | 2030-04-20 | in 1,340 d | 2026-04-29 |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerNCT04221542Parts 1-5 and 7: Incidence of Treatment-emergent Adverse EventsRandomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: AMG 509, Abiraterone, Enzalutamide | Prostate Cancer | 479 | 2030-03-22 | in 1,311 d | 2026-08-06 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)NCT06987539Maximum Observed Concentration (Cmax) of InebilizumabOpen-label · Treatment | Phase 2 | Recruiting | Drug: Inebilizumab | Generalized Myasthenia Gravis | 15 | 2030-03-13 | in 1,302 d | 2026-08-19 |
| Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's DiseaseNCT04528082Area Under the Curve for the Number of Oral Ulcers from Week 0 Through Week 12 (AUCw0-12)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Apremilast, Placebo | Behçet Disease | 60 | 2030-02-07 | in 1,268 d | 2026-07-24 |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674OSRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel | Metastatic Castration-resistant Prostate Cancer | 750 | 2030-01-07 | in 1,237 d | 2026-08-13 |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)NCT06747949Number of Participants with Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 3 | Recruiting | Drug: Dazodalibep | Sjögren's Syndrome | 844 | 2029-12-11 | in 1,210 d | 2026-04-28 |
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)NCT07700238Percentage of Participants With a Durable Platelet Response (DPR)Randomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: Romiplostim, Predniso(lo)ne | Primary Immune Thrombocytopenia | 126 | 2029-09-14 | in 1,122 d | 2026-07-13 |
| Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic LeukemiaNCT04994717Safety run-in: Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | 303 | 2029-09-07 | in 1,115 d | 2026-06-30 |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCNCT06745323Proportion of participants with confirmed objective response to TarlatamabRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Tarlatamab | Small Cell Lung Cancer (SCLC) | 252 | 2029-05-10 | in 995 d | 2026-08-17 |
| A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisNCT03633708Percentage of Participants Achieving a ≥ 30% Reduction from Baseline in Mean iPTH During the Efficacy Assessment Period (EAP)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Etelcalcetide · Other: Standard of Care | Secondary Hyperparathyroidism, Chronic Kidney Disease | 56 | 2029-01-31 | in 896 d | 2026-02-27 |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Tarlatamab, Durvalumab, Carboplatin, Etoposide | Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | 330 | 2029-01-04 | in 869 d | 2026-07-16 |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel | Metastatic Castration-resistant Prostate Cancer | 707 | 2029-01-02 | in 867 d | 2026-05-15 |
| A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular DiseaseNCT06295679observationalTime to CV Death, MI, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization, Whichever Occurs First | — | Recruiting | — | Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease | 7,000 | 2028-12-19 | in 853 d | 2026-06-25 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic LeukemiaNCT07134088Phase 1b: Number of Participants who Experienced Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Blinatumomab | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | 104 | 2028-12-05 | in 839 d | 2026-05-15 |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationNCT06252649PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb | Metastatic Colorectal Cancer | 450 | 2028-09-25 | in 768 d | 2026-07-30 |
| First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT05361395Number of Participants with a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab | Extensive Stage Small Cell Lung Cancer | 184 | 2028-08-28 | in 740 d | 2026-03-03 |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesNCT06570798Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Inebilizumab, Blinatumomab | Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis | 220 | 2028-08-06 | in 718 d | 2026-08-07 |
| AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsNCT07403721Number of Participants with a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: AMG 436 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | 464 | 2028-07-28 | in 709 d | 2026-08-07 |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationNCT07172919Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Sotorasib, Panitumumab | Advanced Solid Tumors | 14 | 2028-07-01 | in 682 d | 2026-07-23 |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE])Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Maridebart Cafraglutide, Placebo | Atherosclerotic Cardiovascular Disease, Overweight, Obesity | 12,800 | 2028-06-30 | in 681 d | 2026-07-24 |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF EventsRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity | 5,056 | 2028-06-30 | in 681 d | 2026-07-02 |
| Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)NCT06180278Change from baseline in serum Ig levels (total Ig, IgG, IgM, IgA, IgE) over timeOpen-label · Treatment | Phase 4 | Active, not recruiting | Other: Blood tests · Drug: Inebilizumab | Neuromyelitis Optica Spectrum Disorder | 32 | 2028-06-26 | in 677 d | 2025-11-21 |
| A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled GoutNCT07388498Number of Participants Achieving Month 6 Response at Weeks 20, 21, 22, 23, and 24Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Pegloticase, Methotrexate | Uncontrolled Gout | 270 | 2028-06-18 | in 669 d | 2026-08-07 |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialNCT07293260Change in NCP Volume from Baseline to Week 72Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Olpasiran, Placebo | Cardiovascular Disease | 406 | 2028-06-15 | in 666 d | 2026-04-16 |
| Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ZL-1310, Tarlatamab, Durvalumab | Small Cell Lung Cancer | 160 | 2028-05-21 | in 641 d | 2026-08-07 |
| Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaNCT07366086Number of Participants with Adverse Events (AEs)Open-label · Supportive care | Phase 3 | Recruiting | Dietary supplement: Vitamin D, Calcium | Osteogenesis Imperfecta | 71 | 2028-04-19 | in 609 d | 2026-06-22 |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsNCT07094113Number of Participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: AMG 410, Pembrolizumab, Panitumumab | KRAS Altered Advanced or Metastatic Solid Tumors | 434 | 2028-04-18 | in 608 d | 2026-07-30 |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes TrialNCT05581303Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs firstRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Placebo, Olpasiran | Atherosclerotic Cardiovascular Disease | 7,297 | 2028-03-31 | in 590 d | 2026-02-27 |
| Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerNCT07140900Number of Participants with Treatment-emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Xaluritamig, Darolutamide, Abiraterone | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | 60 | 2028-03-27 | in 586 d | 2026-07-02 |
| Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisNCT04804553Number of Participants who Achieve American College of Rheumatology Pediatric (ACR) Pedi 30 Response at Week 16Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Apremilast, Placebo | Active Juvenile Psoriatic Arthritis | 60 | 2028-03-21 | in 580 d | 2026-08-06 |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)NCT07037758Number of Participants with Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Tarlatamab, AB248 | Extensive Stage Small Cell Lung Cancer | 380 | 2028-03-18 | in 577 d | 2026-05-29 |
| Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the BoneNCT04586660Objective tumor responseNon-randomized · Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: XGEVA® | Giant Cell Tumor of Bone | 36 | 2028-03-07 | in 566 d | 2025-10-01 |
| Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerNCT07493512Number of Participants with Treatment-emergent Adverse EventsOpen-label · Treatment | Phase 1 | Recruiting | Drug: Xaluritamig | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 40 | 2028-01-30 | in 529 d | 2026-08-07 |
| An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye DiseaseNCT07438405Number of Participants who are Proptosis Responders in the Trial Eye at Week 24 in Participants with TED who are Defined as Primary Nonresponders or Relapsed During the Safety Follow-up in the Parent TrialOpen-label · Treatment | Phase 2 | Recruiting | Drug: AMG 732 | Thyroid Eye Disease | 30 | 2028-01-29 | in 528 d | 2026-07-23 |
| A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaNCT06054555Objective response by Week 49Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: ABP 206, Nivolumab | Melanoma | 633 | 2028-01-25 | in 524 d | 2026-01-12 |
| A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721Area under the serum concentration-time curve (AUC) from time 0 to 21 days (AUC21d) of ABP 234Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: ABP 234, Pembrolizumab (US), Pembrolizumab (EU) | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | 315 | 2028-01-10 | in 509 d | 2026-05-06 |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399Percent Change from Baseline in Body Weight at Week 68Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Maridebart Cafraglutide | Obesity or Overweight | 300 | 2028-01-03 | in 502 d | 2026-07-23 |
| A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)NCT05060016Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by InvestigatorRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Tarlatamab | Relapsed/Refractory Small Cell Lung Cancer | 222 | 2027-12-30 | in 498 d | 2026-07-22 |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144Percent Change in Body Weight from Baseline of the Parent Trial (20210184)Randomized · Double-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Maridebart Cafraglutide, Placebo | Obesity, Overweight, Diabetes Mellitus, Type 2 | 950 | 2027-12-26 | in 494 d | 2026-07-06 |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235Percent Change in Body Weight from Baseline of the Parent Trial (20210181)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Obesity, Overweight | 3,200 | 2027-12-26 | in 494 d | 2026-08-04 |
| A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLNCT04521231Dose Escalation Phase: Number of participants who experience dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Blinatumomab | B Cell Precursor Acute Lymphoblastic Leukemia | 181 | 2027-11-24 | in 462 d | 2026-05-28 |
| Aimovig Pregnancy Exposure RegistryNCT06150781observationalNumber of Infants Experiencing Major Congenital Malformations | — | Recruiting | Drug: erenumab-aooe | Migraine | 2,842 | 2027-10-28 | in 435 d | 2025-11-04 |
| A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes MellitusNCT07590193Number of Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: AMG 127, Placebo | Diabetes Mellitus, Type 2 | 162 | 2027-10-02 | in 409 d | 2026-08-03 |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686Change in Apnea-Hypopnea Index (AHI) from baseline at week 52Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Obesity, Obstructive Sleep Apnea | 250 | 2027-09-29 | in 406 d | 2026-08-04 |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765Change in Apnea-hypopnea Index (AHI) from baseline at Week 52Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Obstructive Sleep Apnea | 250 | 2027-09-29 | in 406 d | 2026-08-14 |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52Randomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: Maridebart cafraglutide, Placebo | Overweight or Obesity and Elevated Liver Fat | 180 | 2027-09-29 | in 406 d | 2026-06-18 |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationNCT07614776Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter scoreRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: ABP 938 8 mg, Aflibercept (US) 8 mg | Neovascular Age-related Macular Degeneration, nAMD | 304 | 2027-07-31 | in 346 d | 2026-08-17 |
| Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.NCT06321601Proportion of Participants Achieving Disease Remission at Week 26 According to the Pediatric Vasculitis Activities Score (PVAS)Non-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Avacopan | Vasculitis | 19 | 2027-07-18 | in 333 d | 2026-07-20 |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036OSRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Tarlatamab, Durvalumab | Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | 563 | 2027-07-05 | in 320 d | 2025-12-17 |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving HemodialysisNCT03969329Percent Change From Baseline in iPTH at Weeks 20 to 26Open-label · Treatment | Phase 3 | Recruiting | Drug: Etelcalcetide | Secondary Hyperparathyroidism | 24 | 2027-06-30 | in 315 d | 2026-03-23 |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356Progression-free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Sotorasib, Pembrolizumab | Non-Small Cell Lung Cancer (NSCLC) | 750 | 2027-06-30 | in 315 d | 2026-08-13 |
| EVOLVE-MI: EVOLocumab Very Early After Myocardial InfarctionNCT05284747Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause deathRandomized · Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: Evolocumab, Routine Lipid Management | Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization | 6,019 | 2027-05-29 | in 283 d | 2025-10-06 |
| Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaNCT05972551Number of Clinical FracturesRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Romosozumab, Bisphosphonate | Osteogenesis Imperfecta | 111 | 2027-05-04 | in 258 d | 2026-05-27 |
| A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland ChinaNCT06588153Change from Baseline in Lumbar Spine BMD PercentageOpen-label · Treatment | Phase 4 | Active, not recruiting | Drug: Prolia® | Glucocorticoid-induced Osteoporosis | 102 | 2027-04-27 | in 251 d | 2026-05-27 |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseaseNCT06987695Percent Change From Baseline in Body Weight at Week 72Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Maridebart cafraglutide, Placebo | Obesity Disease | 279 | 2027-04-27 | in 251 d | 2025-12-17 |
| Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)NCT06598306Number of Participants with Dose-limiting toxicities (DLTs)Non-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: Tarlatamab | Extensive Stage Small Cell Lung Cancer | 220 | 2027-04-24 | in 248 d | 2026-06-26 |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)NCT06700343Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ocrelizumab (US), Ocrelizumab (EU), ABP 692 | Relapsing-remitting Multiple Sclerosis (RRMS) | 152 | 2027-04-19 | in 243 d | 2026-07-27 |
| Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum DisorderNCT05549258Maximum Observed Concentration (Cmax) of InebilizumabOpen-label · Treatment | Phase 2 | Recruiting | Drug: Inebilizumab | Neuromyelitis Optica Spectrum Disorder | 15 | 2027-04-13 | in 237 d | 2025-12-05 |
| A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate AsthmaNCT06637371Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: AMG 691, Placebo | Asthma | 21 | 2027-04-10 | in 234 d | 2026-06-17 |
| A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese VolunteersNCT07745907Maximum Observed Serum Concentration (Cmax) of AMG 691Randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: AMG 691 | Healthy Participants | 28 | 2027-03-31 | in 224 d | 2026-08-04 |
| Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerNCT06613100Number of Participants who Experienced Treatment-emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Xaluritamig, GnRH Antagonist | Prostate Cancer | 40 | 2027-02-17 | in 182 d | 2026-07-31 |
| Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland ChinaNCT06332014Percent change from baseline in bone mineral density (BMD) of lumbar spine at month 12Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: Prolia | Osteoporosis | 102 | 2027-01-23 | in 157 d | 2026-02-12 |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839Percent Change From Baseline in Body Weight at Week 72Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Maridebart Cafraglutide, Placebo | Obesity | 3,853 | 2027-01-21 | in 155 d | 2025-10-20 |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878Percent Change from Baseline in Body Weight at Week 72Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Maridebart cafraglutide, Placebo | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | 1,105 | 2027-01-21 | in 155 d | 2025-12-31 |
| A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseNCT06401044Part A: Number of Participants With Treatment-emergent Adverse EventsRandomized · Double-masked · Treatment | Phase 1/2 | Active, not recruiting | Drug: AMG 732 · Other: Placebo | Thyroid Eye Disease | 94 | 2027-01-06 | in 140 d | 2026-08-10 |
| Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)NCT03319940Number of participants with dose limiting toxicities (DLT) for all indicationsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Tarlatamab, Pembrolizumab, CRS Mitigation Strategies | Small Cell Lung Carcinoma | 269 | 2026-12-31 | in 134 d | 2025-11-19 |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)NCT04185883Number of Participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus | Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation | 610 | 2026-12-17 | in 120 d | 2025-10-22 |
| Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)NCT06430866Area Under the Serum Concentration-time Curve (AUC) From Time 0 to 21 Days (AUC21d) Following the First DoseRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: ABP 234, Pembrolizumab | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | 163 | 2026-12-14 | in 117 d | 2026-04-01 |
| A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)NCT05094336Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet | Advanced MTAP-null Solid Tumors | 329 | 2026-11-30 | in 103 d | 2026-05-28 |
| Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711Maximum Observed Concentration (Cmax) of COCNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: COC, Maridebart Cafraglutide | Overweight, Obesity | 49 | 2026-11-18 | in 91 d | 2026-07-20 |
| A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at Week 25Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: Maridebart cafraglutide, Placebo | Type 2 Diabetes Mellitus | 56 | 2026-11-15 | in 88 d | 2026-06-12 |
| Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).NCT06333951Number of Participants Experiencing Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Anvumetostat, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib | Thoracic Tumors, Non-small Cell Lung Cancer | 49 | 2026-10-31 | in 73 d | 2026-05-28 |
| A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)NCT06360354Number of Participants Experiencing Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Anvumetostat, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX, RMC-6236 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | 120 | 2026-10-31 | in 73 d | 2026-06-01 |
| A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)NCT06593522Objective Response (OR) per RECIST 1.1Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: anvumetostat | MTAP-deleted NSCLC | 61 | 2026-10-31 | in 73 d | 2026-05-28 |
| A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateNCT06245408Change from baseline in ESSPRI scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Dazodalibep, Placebo | Sjögren's Syndrome (SS) | 434 | 2026-10-22 | in 64 d | 2026-01-08 |
| Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerNCT06555796Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Xaluritamig | Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer | 50 | 2026-10-08 | in 50 d | 2026-01-26 |
| Single and Multiple Ascending Dose Study of AMG 513 in Participants With ObesityNCT06585462Number of Participants With Treatment-emergent Adverse Events (TEAE)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: AMG 513, Placebo, AMG 513, Placebo | Cardiometabolic Disease | 80 | 2026-10-01 | in 43 d | 2026-06-22 |
| Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.NCT07545226Area Under the Concentration-time Curve (AUC) from Time 0 Extrapolated to Infinity (AUCinf) of EvolocumabRandomized · Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference) | Healthy Participants | 405 | 2026-09-03 | in 15 d | 2026-07-20 |
| Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityNCT07229157Change from Baseline in QTcF for Maridebart CafraglutideRandomized · Double-masked · Basic science | Phase 1 | Active, not recruiting | Drug: Maridebart Cafraglutide, Moxifloxacin, Placebo for Maridebart Cafraglutide, Placebo for Moxifloxacin | Overweight, Obesity | 81 | 2026-08-26 | in 7 d | 2026-01-23 |
| A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityNCT06104124Change from baseline in European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Dazodalibep, Placebo | Sjogren's Syndrome | 651 | 2026-08-19 | today | 2026-01-16 |
| A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisNCT06088199Number of Participants With Treatment-emergent Adverse EventsOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Apremilast | Plaque Psoriasis | 51 | 2026-08-06 | — | 2025-11-17 |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerNCT03937154Incidence of either a chemotherapy dose delay or reductionRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Romiplostim, Placebo | Chemotherapy-induced Thrombocytopenia | 145 | 2026-03-10actual | — | 2026-04-07 |
| Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)NCT06054113Number of Participants with Complete Remission (CR)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Blinatumomab | B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia | 18 | 2026-01-05actual | — | 2026-01-27 |
| A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye DiseaseNCT06248619Proptosis responder rate (percentage of participants with a ≥ 2-mm reduction from baseline in proptosis in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye).Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Biological: Teprotumumab · Other: Placebo | Thyroid Eye Disease | 89 | 2025-12-23actual | — | 2026-07-07 |
| A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisNCT05565560Achievement of a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at Week 16Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Apremilast | Plaque Psoriasis | 17 | 2025-11-20actual | — | 2026-07-15 |
| Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineNCT03836040Change from baseline in MMDsRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3 · Other: Placebo | Migraine | 457 | 2025-11-19actual | — | 2026-07-16 |
| A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Maridebart Cafraglutide, Placebo | Type 2 Diabetes Mellitus (T2DM) | 409 | 2025-10-06actual | — | 2025-11-25 |
| Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentNCT06502977results2026-04-15Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: Tarlatamab | Extensive Stage Small Cell Lung Cancer | 32 | 2025-03-28actual | — | 2026-07-09 |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNCT05740566results2026-01-05Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Tarlatamab, Lurbinectedin, Topotecan, Amrubicin | Small Cell Lung Cancer (SCLC) | 509 | 2025-01-29actual | — | 2026-01-05 |
| Myasthenia Gravis Inebilizumab TrialNCT04524273results2026-03-10Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study PopulationRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: inebilizumab, IV Placebo | Myasthenia Gravis | 238 | 2024-05-28actual | — | 2026-05-15 |
| A Study of Inebilizumab Efficacy and Safety in IgG4- Related DiseaseNCT04540497results2025-06-25RCP: Time to Disease FlareRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Inebilizumab · Other: Placebo | IgG4 Related Disease | 135 | 2024-04-09actual | — | 2025-12-11 |
| Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AMLNCT03904069Dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091. | Drug: AMG 553 | Relapsed/Refractory Acute Myeloid Leukemia | 0 | 2030-08-07 | in 1,449 d | 2023-06-12 |
| A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLCNCT03392064Incidence of dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Suspendedsponsor's stated reason: Study on enrollment hold, may potentially resume. No active subjects on trial. | Biological: AMG 119 | Small Cell Lung Cancer | 6 | 2028-01-14 | in 513 d | 2025-10-15 |
| Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous DoseNCT07422285Area Under the Concentration-time Curve (AUC) from Time 0 Extrapolated to Infinity (AUCinf) of EvolocumabRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Evolocumab Drug Substance A, Evolocumab Drug Substance B | Healthy Participants, Pharmacokinetics | 405 | 2026-07-24actual | — | 2026-08-17 |
| A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsNCT06131398Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: AMG 355, Pembrolizumab | Advanced Solid Tumors | 77 | 2026-07-22actual | — | 2026-08-11 |
| A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsNCT07313761Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Infinity (AUCinf) of AMG 133Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Maridebart Cafraglutide | Overweight and Obesity | 349 | 2026-07-02actual | — | 2026-08-07 |
| A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)NCT05882877Number of Participants With Treatment-emergent Adverse EventsRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Rocatinlimab · Other: Placebo | Atopic Dermatitis | 2,621 | 2026-07-01actual | — | 2026-07-16 |
| A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)NCT03600883Primary: Number of subjects with treatment-emergent adverse eventsRandomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: sotorasib, Anti PD-1/L1, Midazolam | KRAS p.G12C Mutant Advanced Solid Tumors | 713 | 2026-05-29actual | — | 2026-06-30 |
| Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsNCT07226778Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUCinf) of Maridebart CafraglutideRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Maridebart Cafraglutide | Overweight, Obesity | 348 | 2026-05-28actual | — | 2026-06-17 |
| A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe AsthmaNCT06376045Annualized Rate of Composite Endpoint for Exacerbations (CompEx) Events During the Blinded Treatment PeriodRandomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Rocatinlimab, Placebo | Asthma | 317 | 2026-05-14actual | — | 2026-08-11 |
| A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's SyndromeNCT06312020Change from baseline in European Alliance of Associations for Rheumatology (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) (Population #1)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was terminated by sponsor due to meeting pre-defined criteria for futility. | Drug: HZN-1116, Placebo | Sjogren's Syndrome | 209 | 2026-04-28actual | — | 2026-05-08 |
| A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo NodularisNCT06527404Global: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Week 24Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Rocatinlimab, Placebo | Prurigo Nodularis | 469 | 2026-04-17actual | — | 2026-07-27 |
| A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic FunctionNCT07428525Maximum Observed Plasma Concentration (Cmax) of AMG 133Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AMG 133 | Hepatic Impairment | 36 | 2026-02-26actual | — | 2026-03-11 |
| A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid TumorsNCT05975073Part 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Anvumetostat, IDE397 | MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors | 53 | 2026-02-25actual | — | 2026-04-22 |
| Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic InfectionNCT02910557observationalIncidence Rate | — | Completed | — | Melanoma, Herpetic Infection | 187 | 2026-01-30actual | — | 2026-02-05 |
| A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionNCT05325866Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Bemarituzumab | Solid Tumors | 260 | 2026-01-28actual | — | 2026-06-22 |
| Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid TumorsNCT05800964Percentage of Participants who Experience Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AMG 305 | Advanced Solid Tumors | 37 | 2026-01-22actual | — | 2026-02-17 |
| TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement StudyNCT05002998Percentage of Participants who experience at least 1 treatment-emergent adverse event (TEAE) and the percentage of participants who experience at least 1 treatment emergent AESI during treatment with teprotumumabRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Teprotumumab, Placebo | Thyroid Eye Disease | 313 | 2025-12-19actual | — | 2026-01-15 |
| Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer PatientsNCT07143513observationalNumber of Participants with Treatment-emergent Adverse Events (TEAEs) | — | Completed | Drug: Sotorasib | Non-Small Cell Lung Cancer | 102 | 2025-12-07actual | — | 2026-04-07 |
| Single and Multiple Ascending Dose Study of AMG 378 in Healthy ParticipantsNCT06910709Number of Participants Experiencing a Treatment-emergent Adverse Event (TEAE)Randomized · Double-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: Business Decision | Drug: AMG 378, Placebo | Healthy Volunteers | 48 | 2025-12-02actual | — | 2026-04-02 |
| The Effect of AMG 133 on Gastric EmptyingNCT07429032Maximum Observed Plasma Concentration (Cmax) for AcetaminophenRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AMG 133, Placebo, Acetaminophen | Overweight or Obesity | 57 | 2025-11-26actual | — | 2026-02-24 |
| A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese ParticipantsNCT07142642Maximum Observed Serum Concentration (Cmax) of TeprotumumabRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: Teprotumumab, Placebo | Healthy Volunteers | 20 | 2025-11-22actual | — | 2026-02-27 |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.NCT05322577Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)Non-randomized · Open-label · Basic science | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Bemarituzumab, CAPOX, SOX, Nivolumab | Gastric Cancer, Gastroesophageal Junction Cancer | 72 | 2025-11-21actual | — | 2026-07-29 |
| A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the BodyNCT07429045Maximum Observed Concentration (Cmax) of AMG 133Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AMG 133 | Overweight and Obesity | 44 | 2025-11-21actual | — | 2026-02-24 |
| A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisNCT04175613Adverse Events (AEs)Open-label · Treatment | Phase 3 | Completed | Drug: Apremilast | Psoriasis | 160 | 2025-10-30actual | — | 2025-12-22 |
| A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.NCT06079476Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE)Open-label · Treatment | Phase 4 | Completed | Drug: Romosozumab | Postmenopausal Osteoporosis | 100 | 2025-10-18actual | — | 2025-11-03 |
| Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.NCT05111626Part 1: Number of Participants Who Experienced DLTsRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Study was terminated by sponsor | Drug: Bemarituzumab, Nivolumab, Chemotherapy · Other: Placebo | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 515 | 2025-10-14actual | — | 2026-07-17 |
| Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease PatientsNCT07085117observationalNumber of Participants with Proptosis Response as of the Last IV Infusion Teprotumumab | — | Completed | Drug: Teprotumumab | Thyroid Eye Disease | 5 | 2025-08-10actual | — | 2025-09-08 |
| A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)NCT04998747Number of participants who experience dose-limiting toxicities (DLTs)Non-randomized · Open-label · Basic science | Phase 1 | Withdrawnsponsor's stated reason: Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons. | Drug: AMG 701, AMG 701 | Relapsed/Refractory Multiple Myeloma | 0 | 2025-08-02 | — | 2022-09-27 |
| A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)NCT05633355results2026-07-24Number of Participants Who Experienced Treatment-emergent Serious Adverse Events (TESAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Rocatinlimab | Atopic Dermatitis | 187 | 2025-07-31actual | — | 2026-07-24 |
| A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory GoutNCT06229145results2026-07-01Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Pegloticase · Drug: Methotrexate | Gout | 262 | 2025-07-30actual | — | 2026-07-01 |
| Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)NCT06649006results2026-05-13Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Blinatumomab | B-precursor Acute Lymphoblastic Leukemia | 6 | 2025-07-30actual | — | 2026-05-13 |
| Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeNCT03872401results2026-06-25Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred FirstRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Evolocumab, Placebo | Coronary Heart Disease (CHD) | 12,301 | 2025-07-25actual | — | 2026-06-25 |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationNCT05198934results2026-07-22Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICRRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib | Colorectal Cancer (CRC) | 160 | 2025-07-16actual | — | 2026-07-22 |
| A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)NCT05669014Efficacy of daxdilimab compared to placebo as measured by Total Improvement Score (TIS)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Daxdilimab, Placebo | Idiopathic Inflammatory Myositis | 12 | 2025-07-02actual | — | 2026-05-27 |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionNCT05052801Overall SurvivalRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bemarituzumab, mFOLFOX6, Placebo | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 547 | 2025-06-20actual | — | 2026-05-27 |
| A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentNCT04933695results2026-07-13Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Futility | Drug: Sotorasib | Non-small Cell Lung Cancer | 42 | 2025-05-28actual | — | 2026-07-13 |
| A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityNCT07717814Maximum Observed Concentration (Cmax) of AMG 133Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AMG 133 (frozen liquid), AMG 133 (liquid) | Overweight and Obesity | 154 | 2025-05-22actual | — | 2026-07-21 |
| A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityNCT07310563Maximum Observed Plasma Concentration (Cmax) of AMG 133Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: AMG 133, Ondansetron | Overweight, Obesity | 59 | 2025-05-09actual | — | 2025-12-30 |
| Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus ErythematosusNCT05591222Mean Change in Cutaneous Lupus Erythematosus Disease and Severity Index-Activity (CLASI-A) Score from Baseline to Week 24Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor business decision, not related to safety concerns. | Drug: Placebo, Daxdilimab | Discoid Lupus Erythematosus | 72 | 2025-05-08actual | — | 2026-05-14 |
| A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy ParticipantsNCT06438263Maximum Plasma Concentration (Cmax) of RocatinlimabRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Rocatinlimab, Rocatinlimab | Atopic Dermatitis | 231 | 2025-05-03actual | — | 2026-01-20 |
| A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic DermatitisNCT06224192Proportion of Full-dose Self-administered Rocatinlimab Injections Among Total Attempted Injections up to Week 16Randomized · Open-label · Treatment | Phase 3 | Completed | Combination product: Rocatinlimab Prefilled Syringe, Rocatinlimab AI | Atopic Dermatitis | 151 | 2025-04-11actual | — | 2026-03-25 |
| A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaNCT05907122Area Under the Serum Concentration-time Curve from Time Zero to 28 Days (AUC0-28d)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab | Melanoma | 256 | 2025-03-26actual | — | 2026-03-27 |
| A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)NCT06122649Number of Participants Achieving at least a 75% Reduction (Improvement) From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: apremilast, Placebo | Plaque Psoriasis | 203 | 2025-02-28actual | — | 2026-01-05 |
| A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)NCT05704738Achievement of a Validated Investigator's Global Assessment for Atopic Dermatitis Score of 0 (Clear) or 1 (Almost Clear) with a ≥ 2 Point Reduction From Baseline (vIGA-AD 0/1) at Week 24Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Rocatinlimab, Placebo | Atopic Dermatitis | 532 | 2025-02-27actual | — | 2026-01-16 |
| Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive TherapyNCT05323617Arms 1 and 2: proportion of participants achieving any hematologic response at week 14Non-randomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Operational | Drug: Romiplostim, Antithymocyte Globulin, Cyclosporine A | Severe Aplastic Anemia (SAA) | 0 | 2025-02-25 | — | 2023-09-29 |
| A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic SclerosisNCT04781543results2026-03-20Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Week 52Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated due to meeting pre-defined criteria for futility. | Drug: HZN-825 BID, Placebo, HZN-825 QD | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 301 | 2025-02-24actual | — | 2026-03-20 |
| An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)NCT05626751results2026-01-05Change From Baseline in Forced Vital Capacity Percentage (FVC%) Predicted at Week 52Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was not stopped due to safety reasons | Drug: HZN-825 | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 174 | 2025-02-24actual | — | 2026-01-05 |
| Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineNCT03832998Change from baseline in MMDsRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3 · Other: Placebo | Migraine | 284 | 2025-01-08actual | — | 2026-01-20 |
| A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight LossNCT06761703observationalNumber of Participants with Self-blood Draw Received by Central Laboratory | — | Completed | Device: TAP® Micro Select Device (Touch Activated Phlebotomy) | Obesity | 200 | 2025-01-06actual | — | 2025-01-14 |
| A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityNCT06976372Maximum Concentration (Cmax) of AMG 133Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: AMG 133 | Overweight, Obesity | 120 | 2024-12-27actual | — | 2025-10-08 |
| A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy ParticipantsNCT06411860Placebo-corrected Change From Baseline in QT Corrected for Heart Rate (HR) Interval Based on the Fridericia Correction (QTcF) (ΔΔQTcF) After Olpasiran DosingRandomized · Double-masked · Basic science | Phase 1 | Completed | Other: Placebo · Drug: Olpasiran, Moxifloxacin | Basic Science | 32 | 2024-11-29actual | — | 2025-10-27 |
| A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)NCT05398445results2026-07-23Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Rocatinlimab, Placebo | Atopic Dermatitis | 769 | 2024-11-28actual | — | 2026-07-23 |
| Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisNCT05672199Number of Participants with Treatment-emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The parent study 20170104 was terminated due to the study meeting a prespecified futility rule. Consequently, this study was terminated. | Drug: Efavaleukin alfa, Placebo | Ulcerative Colitis | 25 | 2024-10-31actual | — | 2025-10-15 |
| Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisNCT04987307results2026-01-13Percentage of Participants With Clinical Remission at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated due to meeting a prespecified futility rule and not related to any safety concerns. | Drug: Efavaleukin alfa, Placebo | Ulcerative Colitis | 221 | 2024-10-22actual | — | 2026-01-13 |
| Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusNCT05669599Percent Change From Baseline to Week 52 in Body WeightRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Maridebart Cafraglutide · Drug: Placebo | Obesity, Overweight, Type 2 Diabetes Mellitus | 592 | 2024-10-08actual | — | 2026-01-20 |
| A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)NCT06468826results2026-03-25Maximum Observed Plasma Concentration (Cmax) of AvacopanNon-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Avacopan | End-Stage Renal Disease (ESRD) | 13 | 2024-10-05actual | — | 2026-03-25 |
| A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)NCT05724199results2026-08-06Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Rocatinlimab · Other: Placebo | Atopic Dermatitis | 746 | 2024-09-15actual | — | 2026-08-06 |
| A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy ParticipantsNCT06061523Maximum Plasma Concentration (Cmax) of SotorasibRandomized · Open-label · Basic science | Phase 1 | Withdrawnsponsor's stated reason: FDA and EMA agreed existing data are appropriate for approval and no further BE studies are required. | Drug: Sotorasib | Healthy Participants | 0 | 2024-09-09 | — | 2024-04-12 |
| A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy ParticipantsNCT06268860Maximum Observed Serum Concentration (Cmax) of RocatinlimabRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Rocatinlimab vial injection · Combination product: Rocatinlimab prefilled syringe | Atopic Dermatitis | 240 | 2024-08-30actual | — | 2025-12-23 |
| Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic DermatitisNCT05891119Maximum Observed Serum Concentration (Cmax) of CYP450 SubstrateOpen-label · Basic science | Early Phase 1 | Completed | Dietary supplement: Caffeine, Vitamin K · Drug: Metoprolol, Midazolam, Warfarin, Omeprazole, Rocatinlimab | Atopic Dermatitis | 21 | 2024-08-28actual | — | 2025-12-23 |
| A Study to Evaluate AMG 133 in Chinese Participants With Obesity or OverweightNCT06352892Maximum Observed Plasma Concentration (Cmax) of Maridebart CafraglutideRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Maridebart Cafraglutide | Obesity | 20 | 2024-08-27actual | — | 2026-01-08 |
| A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)NCT05899816results2026-07-23Percentage of Participants With a Positive Anti-tetanus Response at Week 24Randomized · Double-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Rocatinlimab, Placebo | Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | 221 | 2024-08-26actual | — | 2026-07-23 |
| A Study of AMG 757 in Participants With Neuroendocrine Prostate CancerNCT04702737results2025-09-12Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Tarlatamab | Neuroendocrine Prostate Cancer | 41 | 2024-07-22actual | — | 2025-09-12 |
| A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary FibrosisNCT05032066results2025-12-03Core Phase: Change in FVC % Predicted From Baseline to Week 52Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The trial was terminated due to not meeting primary or key secondary endpoints. | Drug: HZN-825, Placebo | Idiopathic Pulmonary Fibrosis | 153 | 2024-07-22actual | — | 2025-12-03 |
| Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)NCT04506086results2025-05-18Number of Participants With Grade 3 and/or 4 Cytokine Release Syndrome (CRS), Neurotoxicity (NT) or Any Adverse Events Resulting in Hospitalization During MDMPOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned. | Drug: Blinatumomab · Device: Current Wearable Heatlth Monitoring System (CWHMS) | B-precursor Acute Lymphoblastic Leukemia | 10 | 2024-07-04actual | — | 2025-05-18 |
| Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic LeukemiaNCT02303821results2025-06-04Phase 1b: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin | Acute Lymphoblastic Leukemia (ALL) | 141 | 2024-06-28actual | — | 2025-06-04 |
| A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate CarcinomaNCT04740034results2025-06-17Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor strategic decision | Drug: AMG 340 | Metastatic Castration-resistant Prostate Cancer | 42 | 2024-06-24actual | — | 2025-06-17 |
| A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)NCT05651711results2026-06-26Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Rocatinlimab · Other: Placebo | Atopic Dermatitis | 726 | 2024-06-05actual | — | 2026-06-26 |
| A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)NCT05267470results2025-03-25Number of Participants Who Experienced a Dose Limiting Toxicity (DLT): Parts 1 and 4Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Business decision not due to safety concerns | Drug: Bemarituzumab, Docetaxel, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel | Squamous-Cell Non-Small-Cell Lung Cancer | 74 | 2024-05-28actual | — | 2025-03-25 |
| AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaNCT02675452results2025-07-09Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: sponsor decision, unrelated to safety | Drug: AMG 176, Azacitidine, Itraconazole | Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia | 141 | 2024-05-27actual | — | 2025-07-09 |
| A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese ParticipantsNCT06214481Maximum Observed Plasma Concentration (Cmax) of RocatinlimabOpen-label · Basic science | Phase 1 | Completed | Drug: Rocatinlimab | Atopic Dermatitis | 20 | 2024-05-27actual | — | 2026-01-07 |
| Observational Study of BlinatumomabNCT03117621observationalProportion of patients with specified AEs as mentioned in description | — | Completed | — | Blincyto Use in Routine Clinical Practice | 279 | 2024-03-20actual | — | 2025-04-04 |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerNCT03362177results2026-02-11Percentage of Participants Who Had Thrombocytopenia-induced Dose ModificationRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Romiplostim · Other: Placebo | Chemotherapy-induced Thrombocytopenia | 165 | 2024-01-25actual | — | 2026-02-11 |
| Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving MethotrexateNCT04511702results2025-01-07Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Pegloticase with MTX | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 191 | 2024-01-18actual | — | 2025-10-20 |
| Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)NCT05540665results2025-03-24Percentage of Participants Who Achieved CRR at Week 48 Through Week 52Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Daxdilimab, Daxdilimab, Placebo (Normal Saline) | Lupus Nephritis | 19 | 2024-01-04actual | — | 2025-03-24 |
| A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)NCT05378529Number of participants with elevated Lp(a) with documented history of ASCVDOpen-label · Basic science | Not applicable | Completed | Other: Lp(a) Screening | Atherosclerotic Cardiovascular Disease | 39,480 | 2023-12-30actual | — | 2025-10-27 |
| AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic LeukemiaNCT05209152results2025-07-14Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision, unrelated to safety | Drug: AMG 176, Azacitidine | Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | 7 | 2023-12-19actual | — | 2025-07-14 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor IndicationsNCT05317078Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor strategic decision | Drug: AMG 794 | Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors | 3 | 2023-12-19actual | — | 2025-10-08 |
| A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese ParticipantsNCT06674941Area Under the Serum Concentration-time Curve (AUC) From Time 0 Extrapolated to Infinity (AUCinf) of TeprotumumabRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Teprotumumab | Healthy Volunteers | 44 | 2023-11-14actual | — | 2024-11-05 |
| Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension StudyNCT05430854results2024-09-19Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: Daxdilimab | Systemic Lupus Erythematosus | 155 | 2023-10-31actual | — | 2024-09-19 |
| Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigraineNCT04252742results2024-08-30Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3Randomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Erenumab, Placebo | Migraine | 512 | 2023-10-26actual | — | 2026-03-31 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal ImpairmentNCT05489614Maximum Observed Serum Concentration (Cmax) of OlpasiranNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Olpasiran | Renal Impairment | 33 | 2023-10-24actual | — | 2025-11-26 |
| Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT04631601Dose exploration only: Number of participants who experience dose limiting toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety. | Drug: Acapatamab, Enzalutamide, Abiraterone, AMG 404 | Metastatic Castration-resistant Prostate Cancer | 65 | 2023-10-23actual | — | 2025-10-07 |
| A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With MigraineNCT04825678results2024-09-19Mean Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) Overall Satisfaction Scale Score at Week 24 by SoCOpen-label · Health services researchStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Erenumab | Migraine | 240 | 2023-09-28actual | — | 2024-09-19 |
| Study of AMG 256 in Adult Subjects With Advanced Solid TumorsNCT04362748Number of Participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AMG 256 | Advanced Solid Tumors | 34 | 2023-09-21actual | — | 2025-10-07 |
| Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With ObesityNCT05406115Number of Participants who Experience a Treatment-emergent Adverse Event (TEAE)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AMG 786 · Other: Placebo | Obesity | 65 | 2023-08-21actual | — | 2025-10-27 |
| Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)NCT05174065results2025-04-09Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Apremilast, Placebo | Palmoplantar Pustulosis | 176 | 2023-08-19actual | — | 2025-04-09 |
| Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia AreataNCT05368103results2025-01-07Percent Change From Baseline in SALT Score at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Daxdilimab | Alopecia Areata | 30 | 2023-08-07actual | — | 2025-01-07 |
| Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004NCT03301857results2024-05-20Number of Participants Experiencing Adverse Events (AEs) of Interest (EOI)Non-randomized · Open-label · Supportive careStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Denosumab | Giant Cell Tumor of Bone | 85 | 2023-07-27actual | — | 2024-05-20 |
| Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)NCT04058028results2024-09-24Number of Participants With a SLE Responder Index (SRI-4) Response at Week 52Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Rozibafusp Alfa, Placebo for Rozibafusp Alfa | Systemic Lupus Erythematosus (SLE) | 244 | 2023-07-25actual | — | 2024-09-24 |
| Denosumab Safety Assessment in Multiple Observational DatabasesNCT02520362observationalIncidence rates of Adverse Events of Special Interest (AESI) | — | Completed | Drug: denosumab, bisphosphonate | Osteoporosis | 517,991 | 2023-07-21actual | — | 2024-11-04 |
| Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver DiseaseNCT04857606Subject Incidence of Treatment-emergent Adverse EventsRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: AMG 609, Placebo | Non-alcoholic Fatty Liver Disease | 47 | 2023-07-19actual | — | 2023-11-07 |
| AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)NCT04885998results2024-10-15Part 1: Number of Participants Who Experienced Dose-limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Tarlatamab, AMG 404 | Small Cell Lung Cancer | 23 | 2023-07-12actual | — | 2025-09-29 |
| A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic DiseasesNCT04948099Treatment-emergent adverse events, treatment-emergent serious adverse events, and adverse events of special interestRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: VIB1116, Placebo | Dendritic Cell -Mediated Rheumatic Diseases | 73 | 2023-07-03actual | — | 2024-12-13 |
| A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaNCT03287908Number of subjects with dose-limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: business decision, not safety reasons. | Drug: AMG 701, Pomalidomide, Dexamethasone | Relapsed/Refractory Multiple Myeloma | 174 | 2023-06-30actual | — | 2025-10-08 |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPCNCT03792841Number of participants with dose-limiting toxicityNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail | Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | 212 | 2023-06-29actual | — | 2025-10-16 |
| Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid TumorsNCT04727554results2025-01-06Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 994, AMG 404 | Advanced Solid Tumors | 11 | 2023-06-05actual | — | 2025-01-06 |
| Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic CancersNCT04117958Incidence of Dose-limiting toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision | Drug: AMG 199 | MUC17-positive Solid Tumors | 58 | 2023-06-01actual | — | 2025-10-14 |
| Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus ErythematosusNCT04680637results2024-06-28Number of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The trial was terminated prematurely as it met pre-defined criteria for futility at IA3. | Drug: Efavaleukin Alfa, Placebo · Other: Standard of Care | Active Systemic Lupus Erythematosus | 168 | 2023-05-22actual | — | 2024-06-28 |
| A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)NCT04762498results2026-05-19Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Pegloticase · Drug: Methotrexate (MTX) | Uncontrolled Gout, Chronic Gout | 54 | 2023-05-18actual | — | 2026-05-19 |
| Study of VIB7734 for the Treatment of Moderate to Severely Active SLENCT04925934results2024-07-23Number of Participants Achieving a BILAG-2004 Index-based Combined Lupus Assessment (BICLA) Response and an OGC Dose ≤ 7.5 mg/Day and ≤ Baseline Dose of Prednisone or Equivalent at Week 48Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: VIB7734 · Other: Placebo | Lupus Erythematosus, Systemic | 214 | 2023-05-16actual | — | 2024-07-23 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)NCT03626662results2026-01-28Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Randomized · Triple-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 890, Placebo | Cardiovascular Disease | 79 | 2023-04-18actual | — | 2026-01-28 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic ImpairmentNCT05481411Maximum Observed Serum Concentration (Cmax) of OlpasiranNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Olpasiran | Hepatic Impairment | 25 | 2023-04-05actual | — | 2025-10-15 |
| A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaNCT03859427results2024-04-18Overall Response Rate (ORR) Per International Myeloma Working Group Uniform Response Criteria (IMWG-URC)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Carfilzomib, Carfilzomib, Lenalidomide, Dexamethasone | Relapsed or Refractory Multiple Myeloma | 454 | 2023-03-31actual | — | 2024-08-13 |
| Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis ImperfectaNCT04545554results2024-04-15Maximum Observed Serum Concentration (Cmax) of RomosozumabNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Romosozumab · Dietary supplement: Calcium, Vitamin D | Osteogenesis Imperfecta | 25 | 2023-03-30actual | — | 2024-04-15 |
| Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaNCT03934684results2024-01-02Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone | Relapsed Refractory Multiple Myeloma | 101 | 2023-03-23actual | — | 2026-05-11 |
| A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye DiseaseNCT04583735results2024-04-26Change From Baseline in Proptosis of Study Eye at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: TEPEZZA · Drug: Placebo | Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease | 62 | 2023-03-17actual | — | 2024-07-01 |
| A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisNCT04761627results2024-01-11Area Under the Plasma Concentration Time Curve (AUC) Over the Dosing Interval (AUCtau) Between Week 52 and Week 64Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ustekinumab, ABP 654 | Psoriasis | 494 | 2023-02-28actual | — | 2024-01-11 |
| A Study of TEPEZZA® Treatment in Participants With Thyroid Eye DiseaseNCT06389578Pharmacokinetics (PK): Area Under the Curve (AUC) of TeprotumumabRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Teprotumumab | Thyroid Eye Disease | 16 | 2023-02-28actual | — | 2024-06-21 |
| Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaNCT03541369results2024-10-10Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Premature discontinuation of study, a strategic decision. | Drug: AMG 427 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | 64 | 2023-02-21actual | — | 2024-10-10 |
| A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)NCT05704725results2025-02-14Percentage of IVT Injections Successfully AdministeredRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ABP 938, Aflibercept | Chorioretinal Vascular Disease | 49 | 2023-02-17actual | — | 2025-02-14 |
| Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALLNCT04524455results2024-04-08Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Blinatumomab, AMG 404, Dexamethasone Premedication | Acute Lymphoblastic Leukemia | 17 | 2023-01-24actual | — | 2024-04-08 |
| Biomarker and Genetic Predictors of Erenumab Treatment ResponseNCT04265755results2024-06-07Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs Over Months 4, 5, and 6 in Relation to mPRSOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Erenumab | Migraine | 1,406 | 2023-01-18actual | — | 2024-06-07 |
| Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous UrticariaNCT04833855results2024-05-01Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo | Chronic Spontaneous Urticaria | 183 | 2022-12-20actual | — | 2025-04-09 |
| Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.NCT03747939results2024-01-05Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Apremilast (CC-10004) · Other: Apremilast (CC-10004) Placebo | Arthritis, Psoriatic | 310 | 2022-12-19actual | — | 2024-10-22 |
| A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque PsoriasisNCT05073315results2024-02-09Area Under the Curve From Time 0 Over the Dosing Interval (AUCtau) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Adalimumab, ABP 501 | Plaque Psoriasis | 425 | 2022-12-19actual | — | 2024-02-09 |
| A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheNCT03971071results2023-10-13Number of Participants With Absence of Medication Overuse Headaches (MOH) at Month 6Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Erenumab 70 mg, Erenumab 140 mg, Placebo | Migraine Headache | 620 | 2022-12-01actual | — | 2025-09-19 |
| Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib TripletNCT04191616results2023-11-08Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Carfilzomib, Dexamethasone, Pomalidomide | Relapsed or Refractory Multiple Myeloma | 54 | 2022-11-30actual | — | 2025-09-04 |
| A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)NCT04478994results2024-04-19Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE) Through Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Poor enrollment | Biological: TEPEZZA · Other: Placebo | Diffuse Cutaneous Systemic Sclerosis | 3 | 2022-11-29actual | — | 2024-06-28 |
| Single and Multiple Ascending Dose Study of AMG 133 in Participants With ObesityNCT04478708results2025-12-10Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: maridebart cafraglutide · Drug: Placebo | Obesity | 110 | 2022-11-18actual | — | 2025-12-10 |
| A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerNCT04466917Objective response rate (ORR)Randomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision to early terminate the study | Drug: ABP 215, Bevacizumab, Paclitaxel, Carboplatin | Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC | 0 | 2022-11-13 | — | 2023-07-03 |
| Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in JapanNCT02808403observationalIncidence of adverse events and adverse drug reactions | — | Completed | Other: No intervention | Hypercholesterolemia, Familial Hypercholesterolemia | 6,000 | 2022-10-31actual | — | 2024-11-21 |
| Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host DiseaseNCT03422627results2023-11-22Phase 1b: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Efavaleukin Alfa | Chronic Graft Versus Host Disease cGVHD | 32 | 2022-10-13actual | — | 2023-11-22 |
| Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple MyelomaNCT02939183results2024-09-26Number of Participants Who Experienced Dose-Limiting Toxcity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Immediate Release (IR) Formulation, Gastro-Retentive (GR) Formulation, Dexamethasone, Pomalidomide | Relapsed or Refractory Multiple Myeloma | 61 | 2022-10-06actual | — | 2024-09-26 |
| Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian ParticipantsNCT04987333results2024-03-29Maximum Observed Serum Concentration (Cmax) of Efavaleukin AlfaNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Efavaleukin alfa | Inflammatory Diseases | 32 | 2022-10-03actual | — | 2024-03-29 |
| A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy VolunteersNCT05497557results2024-01-19Maximum Observed Plasma Concentration (Cmax) of SotorasibOpen-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Omeprazole, Sotorasib | Healthy Volunteers | 16 | 2022-09-08actual | — | 2024-01-19 |
| A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's SyndromeNCT04129164results2025-04-30Population 1: Change From Baseline in ESSDAI at Day 169Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: VIB4920, Placebo | Sjögren's Syndrome | 183 | 2022-09-01actual | — | 2025-04-30 |
| Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase MonotherapyNCT04772313results2023-10-10Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Pegloticase · Drug: Methotrexate (MTX) | Uncontrolled Gout | 11 | 2022-08-23actual | — | 2024-06-27 |
| APremilast After FumaRic Acid Ester TreatmentNCT02954081observationalMean absolute value of the overall TSQM score at week 24 of apremilast (APR) therapy (phase II). | — | Completed | Drug: Phase I: Fumaric acid esters. Phase II: Apremilast | Psoriasis | 687 | 2022-08-15actual | — | 2023-01-26 |
| Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of SimvastatinNCT06207682Maximum Observed Plasma Concentration (Cmax) of SimvastatinRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Avacopan, Simvastatin | Healthy Volunteers | 32 | 2022-08-11actual | — | 2024-01-17 |
| Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).NCT04303780results2023-05-10Progression-free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: AMG 510, Docetaxel | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | 345 | 2022-08-02actual | — | 2026-07-22 |
| AMG 404 in Patients With Advanced Solid TumorsNCT03853109results2024-12-13Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 404 | Advanced Solid Tumors | 171 | 2022-07-19actual | — | 2025-07-20 |
| A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney TransplantNCT04046549results2023-10-10Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Week 24Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Belatacept, VIB4920, Thymoglobulin, Methylprednisolone | Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation | 25 | 2022-07-18actual | — | 2024-12-27 |
| A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]NCT04270747results2024-01-05Mean Change From Baseline in BCVA at Week 8Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ABP 938, Aflibercept | Neovascular (Wet) Age-related Macular Degeneration (AMD) | 576 | 2022-07-18actual | — | 2025-09-10 |
| A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 TabletsNCT05327491results2023-12-14Period 1 and 2: Maximum Observed Plasma Concentration (Cmax) of SotorasibRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Sotorasib | Healthy Participants | 146 | 2022-07-17actual | — | 2023-12-14 |
| A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNHNCT03818607results2023-05-23LDH Level at Week 27 (Parallel Comparison)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ABP 959, Eculizumab | Paroxysmal Nocturnal Hemoglobinuria | 42 | 2022-07-12actual | — | 2023-05-23 |
| Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)NCT03335488results2023-07-10Rate of Treatment Success (Percentage of Participants Defined as Treatment Success at Week 4) During the Initial Treatment PeriodRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: RAVICTI, NaPBA | Urea Cycle Disorder | 16 | 2022-07-05actual | — | 2024-07-01 |
| A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The NetherlandsNCT02875184observationalPercentage of patients with a Health Assessment Questionnaire - Disability Index (HAQ-DI) score of ≤ 0.5 or with a decrease of ≥ 0.3 of the HAQ-DI score compared with baseline | — | Completed | — | Arthritis, Psoriatic | 200 | 2022-06-30actual | — | 2023-10-10 |
| Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction AdenocarcinomaNCT04260191results2024-01-25Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Business Decision | Drug: AMG 910 | Gastric and Gastroesophageal Junction Adenocarcinoma | 15 | 2022-06-02actual | — | 2024-01-25 |
| Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisNCT03701763results2023-12-07Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Apremilast (CC-10004) · Other: Placebo | Psoriasis | 245 | 2022-04-25actual | — | 2024-12-16 |
| Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple MyelomaNCT03836053results2024-01-05Number of Participants With Dose-limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Amgen re-evaluated the portfolio and decided to discontinue clinical development activities for AMG 420. | Drug: AMG 420 | Relapsed and/or Refractory Multiple Myeloma | 23 | 2022-04-21actual | — | 2025-09-11 |
| Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian ParticipantsNCT05056246results2025-02-25Maximum Observed Plasma Concentration (Cmax) of Intact AMG 133Randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 133 | Healthy Participants | 34 | 2022-04-08actual | — | 2025-02-25 |
| Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis ImperfectaNCT03638128results2022-12-20Number of Participants With Adverse Events, Serious Adverse Events, and Adverse Events of Special InterestNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants | Drug: Denosumab, Alternative osteoporosis medications | Osteogenesis Imperfecta (OI) | 75 | 2022-03-28actual | — | 2022-12-20 |
| Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OINCT02352753results2022-12-28Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score at 12 MonthsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants | Drug: Denosumab | Osteogenesis Imperfecta | 153 | 2022-03-26actual | — | 2022-12-28 |
| Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label ExtensionNCT02867813results2023-02-28Number of Participants Who Experienced an Adverse EventOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Evolocumab | Dyslipidemia | 5,035 | 2022-03-21actual | — | 2023-04-07 |
| Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic ImpairmentNCT04887064results2024-04-19Maximum Observed Plasma Concentration (Cmax) of SotorasibNon-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Sotorasib | Hepatic Impairment | 20 | 2022-03-09actual | — | 2024-04-19 |
| Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European CountriesNCT03080935results2023-01-11Number of Participants Who Experienced an Adverse EventOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Amgen business decision to close study early | Drug: Evolocumab | Dyslipidemia | 1,600 | 2022-03-04actual | — | 2024-05-29 |
| A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy ParticipantsNCT05048784results2023-09-18Maximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and BRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Sotorasib | Healthy Participants | 145 | 2022-02-18actual | — | 2023-09-18 |
| Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611NCT02509507results2022-12-30Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Talimogene Laherparepvec, Pembrolizumab | Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors | 127 | 2022-02-14actual | — | 2024-08-06 |
| Study of Talimogene Laherparepvec In Children With Advanced Non CNS TumorsNCT02756845results2024-02-05Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Talimogene Laherparepvec | Advanced Non CNS Tumors | 15 | 2022-01-17actual | — | 2024-02-20 |
| A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisNCT04607980results2023-12-15PASI Percent Change From Baseline to Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ABP 654, Ustekinumab | Plaque Psoriasis | 563 | 2022-01-13actual | — | 2024-12-12 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular LymphomaNCT03571828results2024-03-22Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Amgen decided to discontinue study because of a business decision and not because of safety reasons | Drug: AMG 562 | Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL) | 10 | 2022-01-12actual | — | 2024-03-22 |
| A Phase 1 Study of AMG 330 in Subjects With Myeloid MalignanciesNCT02520427results2024-07-31Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Amgen strategic business decision to cancel following portfolio review, re-prioritization. | Drug: AMG 330 | Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome | 95 | 2022-01-09actual | — | 2024-07-31 |
| Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased DonorNCT04174677Number of subjects with safety events (treatment-emergent adverse events, treatment-emergent serious adverse events, or treatment-emergent adverse events of special interest) during the course of the studyRandomized · Open-label · Prevention | Phase 2 | Withdrawnsponsor's stated reason: Stopped due to no enrollment | Drug: Inebilizumab, VIB4920, Inebilzumab+VIB4920 | Highly Sensitized Patients on Waiting List for Kidney Transplantation | 0 | Dec 2021 | — | 2024-06-21 |
| AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).NCT04380753results2024-03-22Number of Participants With Dose-limiting Toxicities (DLT)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 510 | Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation | 12 | 2021-12-31actual | — | 2026-05-06 |
| A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid ArthritisNCT04163991results2023-02-14Change From Baseline to Day 113 in DAS28-CRPRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: VIB4920, Placebo | Rheumatoid Arthritis | 78 | 2021-12-28actual | — | 2024-12-17 |
| Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding StudyNCT04270760results2023-08-23Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Olpasiran, Placebo | Cardiovascular Disease | 281 | 2021-12-27actual | — | 2026-03-31 |
| Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced OsteoporosisNCT03164928results2024-07-19Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 MonthsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Denosumab · Other: Placebo | Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis | 24 | 2021-12-13actual | — | 2024-07-19 |
| Study of AMG 160 in Subjects With Non-Small Cell Lung CancerNCT04822298results2024-07-05Number of Participants Who Experience One or More Dose-limiting Toxicities (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Amgen made a business decision to discontinue AMG 160 20180273 | Drug: AMG 160 | Non-small Cell Lung Cancer, NSCLC | 3 | 2021-12-08actual | — | 2024-07-05 |
| A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult ParticipantsNCT05909852AUCinf of ABP 501-HCF and ABP 501-LCFRandomized · Single-masked · Basic science | Phase 1 | Completed | Drug: ABP 501-HCF, ABP 501-LCF | Adalimumab | 372 | 2021-11-24actual | — | 2026-06-25 |
| AMG 334 20160172 Pediatric Migraine PK Study.NCT03499119results2024-03-28Time to Maximum Concentration (Tmax) of ErenumabRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3 | Migraine | 53 | 2021-11-23actual | — | 2024-05-28 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)NCT04987320results2025-02-10Maximum Observed Concentration (Cmax) of OlpasiranRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Olpasiran | Elevated Serum Lipoprotein(a) | 24 | 2021-11-12actual | — | 2025-02-10 |
| Post-Marketing Surveillance Study of OTEZLANCT03284879observationalAdverse Events (AEs) | — | Completed | — | Psoriasis | 1,086 | 2021-10-31actual | — | 2025-09-08 |
| A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology PracticeNCT02740218observationalThe Patient Benefit Index (PBI) outcome score | — | Completed | Other: Patient questionnaire | Psoriasis | 610 | 2021-10-27actual | — | 2024-03-04 |
| A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic ArthritisNCT03783026results2022-12-19Change From Baseline in the Composite Score of BME, Synovitis, and Tenosynovitis Assessed by PsAMRIS at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Apremilast | Psoriatic Arthritis | 123 | 2021-10-26actual | — | 2025-02-21 |
| A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological TreatmentNCT03828045observationalTreatment persistence at 6 months after initiating apremilast treatment | — | Completed | Drug: Apremilast | Arthritis, Psoriatic | 119 | 2021-10-20actual | — | 2024-06-05 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus ErythematosusNCT03451422results2023-07-19Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)Randomized · Triple-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Efavaleukin Alfa, Placebo | Systemic Lupus Erythematosus | 35 | 2021-10-12actual | — | 2023-07-19 |
| Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy ParticipantsNCT05045638results2023-08-14Maximum Observed Plasma Concentration (Cmax) of RosuvastatinNon-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Rosuvastatin, Sotorasib | Healthy Participants | 13 | 2021-10-10actual | — | 2023-08-14 |
| Study of Sustained Benefit of AMG334 in Adult Episodic Migraine PatientsNCT03927144results2022-10-25Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: AMG334, Oral Prophylactic | Episodic Migraine | 621 | 2021-10-01actual | — | 2023-11-18 |
| Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote MonitoringNCT04292275Time to Change or Decision That Heart Failure Therapy is OptimalRandomized · Open-label · Supportive care | Not applicable | Terminatedsponsor's stated reason: Study closed prematurely due to enrollment challenges exacerbated by COVID-19. | Device: Biobeat Wrist Watch · Other: Standard of Care | Heart Failure | 18 | 2021-10-01actual | — | 2023-08-08 |
| Registry Study for Talimogene LaherparepvecNCT02173171observationalTalimogene Laherparepvec Related Adverse Events | — | Completed | Other: Information collection | Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial | 185 | 2021-09-23actual | — | 2021-09-30 |
| An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital PsoriasisNCT03777436results2022-12-15Percentage of Participants With a Modified sPGA-G Response at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Apremilast · Other: Placebo | Psoriasis | 289 | 2021-09-23actual | — | 2024-05-14 |
| Single and Multiple Ascending Dose Study of AMG 171 in Subjects With ObesityNCT04199351results2024-09-19Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified. | Drug: AMG 171, Placebo | Obesity | 60 | 2021-09-10actual | — | 2024-09-19 |
| A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaNCT02961881results2024-02-02Number of Participants With Dose Limiting-Toxicities (DLTs) After SC AdministrationOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: blinatumomab | Non-Hodgkin's Lymphoma | 35 | 2021-09-02actual | — | 2024-02-02 |
| Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).NCT04068181results2022-09-09Objective Response Rate (ORR) Per Modified RECIST v1.1Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Talimogene laherparepvec, Pembrolizumab | Melanoma | 72 | 2021-08-19actual | — | 2025-01-07 |
| Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United StatesNCT02993120observationalLow-density lipoprotein (LDL) treatment patterns | — | Completed | — | Medical Conditions to be Studied, Dyslipidemia, ASCVD Management | 5,006 | 2021-08-06actual | — | 2023-05-03 |
| Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized PatientsNCT04590586results2022-06-29Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo | COVID-19 | 515 | 2021-08-03actual | — | 2022-06-29 |
| Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic MigraineNCT03912337results2022-07-20Sum of Monthly Changes From Baseline in Modified MIDAS Total Score Over the 6-month DBTPRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: Terminated \[Study would not complete enrollment target until 2026 with results available in 2027. The information will not be useful at that time.\] | Drug: Placebo, Erenumab | Migraine | 29 | 2021-07-28actual | — | 2022-07-20 |
| A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in FranceNCT03757013observationalProportion of patients with Patient Benefit Index score (PBI-S) ≥1 at 6 months after initiation of apremilast. | — | Completed | Drug: Apremilast | Psoriasis | 453 | 2021-07-21actual | — | 2021-12-03 |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.NCT03343847Chemotherapy dose delay or reductionRandomized · Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Study was not feasible | Biological: Romiplostim · Other: Placebo | Chemotherapy-induced Thrombocytopenia | 0 | 2021-07-17 | — | 2018-01-19 |
| Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney TransplantNCT04087720results2022-07-26Percentage of Serum Uric Acid (sUA) < 6 mg/dL Responders During Month 6Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Pegloticase | Uncontrolled Gout, Kidney Transplant | 20 | 2021-07-06actual | — | 2024-06-26 |
| Study of AMG 596 in Patients With EGFRvIII Positive GlioblastomaNCT03296696results2024-10-29Number of Participants With Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Amgen business decision | Drug: AMG 596, AMG 404 | Glioblastoma or Malignant Glioma | 30 | 2021-07-01actual | — | 2024-10-29 |
| Chart Review of Repatha® in Subjects With HyperlipidaemiaNCT02770131observationalDescription of clinical characteristics of subjects initiated on Repatha® | — | Completed | — | Hypercholesterolaemia | 1,986 | 2021-06-30actual | — | 2024-06-06 |
| Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)NCT02624869results2022-01-14Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Evolocumab | Familial Hypercholesterolemia | 163 | 2021-06-01actual | — | 2024-05-29 |
| Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA StudyNCT02792478observationalDetection rate of RAS mutations in liquid biopsies in subjects with RAS wild-type mCRC at baseline. | — | Completed | — | RAS Wild Type mCRC | 238 | 2021-05-31actual | — | 2024-05-13 |
| A Study of TEPEZZA Subcutaneous Administration in Healthy AdultsNCT06563856Cohort 1, 2, and 4: Area Under the Serum Concentration-time Curve (AUC) From Time 0 Extrapolated to Infinity (AUCinf) of TEPEZZANon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: TEPEZZA, EDP | Bioavailability, Bioequivalence | 37 | 2021-05-27actual | — | 2024-08-21 |
| Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)NCT03608657observationalThe rate of achieving Low Disease Activity (LDA) | — | Completed | Drug: Apremilast | Arthritis, Psoriatic | 102 | 2021-04-12actual | — | 2024-06-05 |
| Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled GoutNCT03994731results2022-05-16Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Pegloticase · Drug: methotrexate, placebo, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone · Dietary supplement: folic acid | Gout | 152 | 2021-03-17actual | — | 2024-06-26 |
| Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected MelanomaNCT02263508results2022-05-16Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminated | Drug: Talimogene Laherparepvec, Pembrolizumab, Placebo | Melanoma | 713 | 2021-03-11actual | — | 2022-11-14 |
| Controlled Trial Evaluating Avacopan in C3 GlomerulopathyNCT03301467results2022-10-14Change From Baseline to Week 26 in the C3G Histologic Index for Disease Activity - Subjects With Elevated C5b-9Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Avacopan, Avacopan Matching Placebo | C3 Glomerulopathy (C3G) | 57 | 2021-03-03actual | — | 2025-03-13 |
| A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of LifeNCT03774875results2022-01-13Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Apremilast, Placebo | Psoriasis | 277 | 2021-02-01actual | — | 2025-07-10 |
| A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical PracticeNCT04031027observationalMean age of the patients treated with apremilast | — | Completed | Drug: Apremilast | Plaque Psoriasis | 184 | 2021-01-27actual | — | 2024-03-04 |
| A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar PustulosisNCT04057937results2022-01-06Percentage of Participants Who Achieve a PPPASI-50 at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Apremilast, Placebo | Palmoplantaris Pustulosis | 90 | 2021-01-18actual | — | 2024-07-17 |
| Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)NCT03852472results2024-03-15Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Avacopan · Other: Placebo | Hidradenitis Suppurativa, Acne Inversa | 435 | 2021-01-14actual | — | 2025-03-17 |
| ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st LineNCT02624895observationalEORTC QLQ C30 questionnaire score | — | Completed | — | Metastatic Colorectal Cancer | 296 | 2020-12-31actual | — | 2021-01-22 |
| Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)NCT03224819results2023-09-01Number of Participants With Treatment-emergent Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Early Phase 1 | Terminatedsponsor's stated reason: Priortization of other Programs | Drug: Emerfetamab | Acute Myeloid Leukemia | 46 | 2020-12-28actual | — | 2023-09-01 |
| The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)NCT04197453observationalIncident event rate for the composite of all-cause mortality, non-fatal myocardial infarction (MI), and non-fatal ischemic stroke (IS). | — | Terminatedsponsor's stated reason: Sponsor decision | — | ASCVD | 752 | 2020-12-21actual | — | 2021-10-15 |
| Imaging of Coronary Plaques in Participants Treated With EvolocumabNCT03570697results2021-11-24Absolute Change From Baseline in Minimum FCTRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Evolocumab, Placebo, Statin therapy | Coronary Artery Disease (CAD) | 164 | 2020-12-18actual | — | 2022-05-03 |
| Osteonecrosis of the Jaw (ONJ) Case RegistryNCT01666106observationalResolution rate and time to ONJ resolution | — | Completed | — | Osteonecrosis of the Jaw | 327 | 2020-12-16actual | — | 2020-12-21 |
| Study to Evaluate the Safety of Repatha® in PregnancyNCT02906124observationalAny incident of congenital anomaly | — | Terminated | — | Hypercholesterolaemia, Pregnancy | 4 | 2020-11-06actual | — | 2020-12-22 |
| Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)NCT03340766results2022-02-25Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Blinatumomab, Pembrolizumab | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | 31 | 2020-11-06actual | — | 2024-10-17 |
| Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid LeukemiaNCT04478695results2024-03-08Number of Participants Who Experienced Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Amgen Decision | Drug: AMG 330, Pembrolizumab | Relapsed or Refractory Acute Myeloid Leukemia | 1 | 2020-10-23actual | — | 2024-03-08 |
| A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsNCT05599828Maximum Observed Plasma Concentration (Cmax) of AMG 510Open-label · Basic science | Phase 1 | Completed | Drug: AMG 510, Omeprazole, Famotidine | Healthy Participants | 14 | 2020-09-13actual | — | 2024-12-12 |
| Evolocumab Pregnancy Exposure RegistryNCT02957604observationalRate of major structural defects | — | Terminated | Drug: evolocumab | Hypercholesterolemia; ASCVD; Pregnancy | 140 | 2020-09-02actual | — | 2020-12-17 |
| Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant MelanomaNCT03064763results2021-06-14Number of Participants Who Experienced One or More Dose Limiting Toxicities (DLTs)Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Talimogene laherparepvec | Unresectable Stage IIIB-IV Malignant Melanoma | 18 | 2020-08-03actual | — | 2023-08-09 |
| A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and DermatomyositisNCT03817424Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: VIB7734, Placebo | Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis | 31 | 2020-07-20actual | — | 2024-12-13 |
| A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic SyndromeNCT03703908results2024-02-06The Number of Subjects With a Reduction in Urine Protein to Creatinine Ratio (UPCR) of at Least 20%Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Program not advancing | Drug: CCX140-B | Focal Segmental Glomerulosclerosis | 5 | 2020-06-24actual | — | 2025-03-17 |
| A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy ParticipantsNCT05571163Maximum Observed Plasma Concentration (Cmax) of AMG 510Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: AMG 510 | Healthy Participants | 13 | 2020-06-14actual | — | 2022-10-07 |
| Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension StudyNCT03461211results2021-07-19Percentage of Participants With a ≥ 2 mm Reduction From Baseline in the Study Eye Without Deterioration of Proptosis in the Fellow Eye at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Teprotumumab | Thyroid Eye Disease | 51 | 2020-06-08actual | — | 2024-06-28 |
| Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesNCT03256344results2021-06-09Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: Talimogene Laherparepvec, Atezolizumab | Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer | 36 | 2020-05-26actual | — | 2024-05-14 |
| A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic DermatitisNCT03809663results2022-03-10Number of Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) (IGA 0/1) at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Tezepelumab as a monotherapy in atopic dermatitis did not reach the targeted efficacy level pre-established for this patient population. | Drug: Tezepelumab · Other: Placebo | Atopic Dermatitis | 251 | 2020-05-12actual | — | 2022-03-10 |
| A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical TherapyNCT03930186results2022-01-20Percentage of Participants Who Achieved an sPGA Score of Clear (0) or Almost Clear (1) at Week 16Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Apremilast, Topical Therapy | Plaque Psoriasis | 152 | 2020-05-08actual | — | 2022-01-20 |
| Phase 1b Study of CCX872-B in Patients With Pancreatic AdenocarcinomaNCT02345408progression-free survivalOpen-label · Treatment | Phase 1 | Completed | Drug: CCX872-B | Pancreatic Cancer | 54 | 2020-05-06actual | — | 2025-02-27 |
| Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed DyslipidemiaNCT03433755results2021-08-20Co-Primary Endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Prematurely Discontinued Amgen decision | Drug: evolocumab, placebo | Primary Hypercholesterolemia, Mixed Dyslipidemia | 259 | 2020-04-24actual | — | 2023-03-27 |
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)NCT03299244results2021-04-30Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority AnalysisRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Etelcalcetide, Cinacalcet | Secondary Hyperparathyroidism, Chronic Kidney Disease | 637 | 2020-04-08actual | — | 2021-04-30 |
| An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the USNCT02783651observationalTreatment patterns in patients with Ph- R/R ALL | — | Completed | Other | Relapsed/Refractory Acute Lymphoblastic Leukemia | 212 | 2020-03-31actual | — | 2020-04-27 |
| A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male SubjectsNCT05578859Area under the concentration-time curve (AUC) from time zero to infinity (AUCinf)Open-label · Basic science | Phase 1 | Completed | Drug: AMG 510 | Healthy Subjects | 8 | 2020-03-24actual | — | 2022-11-07 |
| Real-world Use of Carfilzomib Among Multiple Myeloma Patients in EuropeNCT03091127observationalCarfilzomib starting dose | — | Completed | — | Multiple Myeloma | 705 | 2020-03-17actual | — | 2022-12-12 |
| A Controlled Trial of Erenumab in Migraine PreventionNCT03812224results2021-03-04Change From Baseline in Mean Monthly Migraine Days (MMD) Over Months 4, 5, and 6 of the Double-blind Treatment PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Erenumab, Placebo | Migraine | 261 | 2020-03-16actual | — | 2024-02-21 |
| Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHLNCT02910063results2021-01-13Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Blinatumomab | B-Cell Non Hodgkin Lymphoma | 41 | 2020-03-12actual | — | 2021-01-13 |
| Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and EfficacyNCT03721172results2021-05-17Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled PhaseRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Apremilast · Other: Placebo | Psoriasis | 595 | 2020-03-06actual | — | 2024-05-29 |
| A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With OmeprazoleNCT04139226Adverse Events (AEs)Open-label · Treatment | Phase 1 | Completed | Drug: CC-11050 | Healthy Volunteers | 44 | 2020-02-27actual | — | 2020-06-22 |
| Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)NCT01948427results2021-02-18observationalMean Blood Ammonia Levels Over Time, by Last Known Ammonia-Scavenging MedicationStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: the study was terminated due to the primary end point being met. | — | Urea Cycle Disorder | 203 | 2020-02-24actual | — | 2024-07-01 |
| A Study of CCX140-B in Subjects With FSGSNCT03536754results2023-12-05Change From Baseline in UPCR at Week 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Other: Placebo · Drug: CCX140-B, CCX140-B, CCX140-B | FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis | 46 | 2020-02-19actual | — | 2025-03-13 |
| An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant RecipientsNCT03619187pVO2Open-label · Supportive care | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: Ivabradine | Heart Transplantation, Elevated Resting Heart Rate | 0 | 2020-02-19 | — | 2018-11-19 |
| Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)NCT01327612results2021-02-21Number of Participants With Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Modified FOLFOX6 · Biological: Conatumumab, Ganitumab, Bevacizumab | Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors | 12 | 2020-02-05actual | — | 2021-02-21 |
| Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsNCT05581992Maximum Observed Plasma Concentration (Cmax) of AMG 510Open-label · Basic science | Phase 1 | Completed | Drug: AMG 510, Omeprazole | Healthy Participants | 14 | 2020-01-26actual | — | 2025-03-18 |
| A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy ParticipantsNCT05988034Change from Baseline in QTcFRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin | Electrocardiography | 58 | 2020-01-22actual | — | 2023-08-14 |
| A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology CentersNCT03512353results2021-01-08Number of Participants Who Completed 12 Cycles of TreatmentOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Dexamethasone, Carfilzomib | Relapsed or Refractory Multiple Myeloma | 7 | 2020-01-16actual | — | 2021-01-08 |
| Observational Study of Apremilast in Patients With Psoriasis in The NetherlandsNCT02652494observationalPercentage of patients with Dermatology Life Quality Index (DLQI) ≤ 5 points | — | Completed | — | Psoriasis | 154 | 2019-12-31actual | — | 2024-05-13 |
| A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsNCT05568082Maximum Observed Plasma Concentration (Cmax) of AMG 510Open-label · Basic science | Phase 1 | Completed | Drug: AMG 510, Itraconazole | Healthy Participants | 14 | 2019-12-17actual | — | 2025-03-05 |
| Multiple Ascending Dose Study of AMG 598 in Adults With ObesityNCT03757130results2023-09-14Number of Participants With Treatment-emergent Adverse EventsRandomized · Double-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 598, Placebo, Liraglutide | Obesity | 50 | 2019-12-16actual | — | 2023-09-14 |
| Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid ArthritisNCT03410056results2021-06-04Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Amgen made a business decision not to proceed with Phase 2. | Drug: Efavaleukin alfa, Placebo | Rheumatoid Arthritis RA | 36 | 2019-12-10actual | — | 2021-06-22 |
| Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis RemissionNCT02373813results2020-12-19Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission (≤ 3.3) at Week 48: Etanercept Monotherapy vs. Methotrexate MonotherapyRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: etanercept pre-filled syringe subcutaneous injection, Oral methotrexate, Placebo for etanercept subcutaneous injection, Placebo for methotrexate · Dietary supplement: Folic acid (non-investigational product) | Rheumatoid Arthritis | 371 | 2019-12-06actual | — | 2023-01-11 |
| A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy ParticipantsNCT05577624Maximum Plasma Concentration (Cmax) of AMG 510Open-label · Basic science | Phase 1 | Completed | Drug: AMG 510, Rifampin | Healthy Participants | 14 | 2019-12-01actual | — | 2025-03-18 |
| Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial HypercholesterolemiaNCT03403374results2020-11-03Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: evolocumab | Homozygous Familial Hypercholesterolemia HoFH | 30 | 2019-11-27actual | — | 2024-05-29 |
| Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) DisordersNCT02392559results2020-07-15Percent Change From Baseline to Week 24 in LDL-CRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Evolocumab, Placebo | Heterozygous Familial Hypercholesterolemia | 158 | 2019-11-25actual | — | 2022-11-08 |
| Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy ParticipantsNCT05550129Maximum Plasma Concentration (Cmax) of MetforminOpen-label · Basic science | Phase 1 | Completed | Drug: AMG 510, Metformin | Healthy Volunteers | 13 | 2019-11-25actual | — | 2025-03-05 |
| A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsNCT05581758Maximum Plasma Concentration (Cmax) of AMG 510Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: AMG 510 | Healthy Participants | 14 | 2019-11-25actual | — | 2025-03-05 |
| Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy ParticipantsNCT05598281Maximum Plasma Concentration (Cmax) of Digoxin Administered AloneOpen-label · Basic science | Phase 1 | Completed | Drug: AMG 510, Digoxin | Healthy Participants | 14 | 2019-11-19actual | — | 2025-04-02 |
| Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in SpainNCT03539419observationalPercentage of subjects achieving PBI ≥ 1 | — | Completed | — | Psoriasis | 153 | 2019-11-02actual | — | 2024-06-05 |
| Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaNCT02335983results2020-11-06Number of Participants With Adverse Events (AEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Carfilzomib, Lenalidomide, Dexamethasone | Multiple Myeloma | 107 | 2019-10-28actual | — | 2020-11-06 |
| Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled GoutNCT03635957results2020-11-18Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Pegloticase · Drug: Methotrexate (MTX), Standard Gout Flare Prophylaxis, Infusion Reaction (IR) Prophylaxis · Dietary supplement: Folic Acid | Gout | 14 | 2019-10-23actual | — | 2024-06-26 |
| Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid ArthritisNCT03156023results2023-04-03Number of Participants With Treatment-emergent Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Rozibafusp Alfa, Placebo | Rheumatoid Arthritis | 34 | 2019-10-17actual | — | 2024-05-14 |
| Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)NCT03298412results2020-09-11MRD-Negative Rate at the End of Cycle 1Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Early Closure due to rare patient population | Drug: Blinatumomab | High-risk Diffuse Large B-cell Lymphoma | 10 | 2019-09-30actual | — | 2020-09-11 |
| Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple MyelomaNCT01881789results2021-03-03Number of Participants With Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation. | Drug: Oprozomib, Lenalidomide, Dexamethasone, Cyclophosphamide | Multiple Myeloma | 22 | 2019-09-23actual | — | 2022-11-14 |
| A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated VasculitisNCT02994927results2022-09-09Percentage of Subjects Achieving Disease Remission at Week 26Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Avacopan, Prednisone, Cyclophosphamide, Azathioprine · Biological: Rituximab | ANCA-Associated Vasculitis | 331 | 2019-09-07actual | — | 2025-03-24 |
| Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)NCT03476239results2020-09-14Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With BlinatumomabOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Blinatumomab, Dexamthasone | Acute Lymphoblastic Leukemia | 121 | 2019-08-21actual | — | 2023-02-08 |
| Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic AcidNCT01967160observational1. Incidence proportions of medically confirmed osteonecrosis of the jaw (ONJ) in XGEVA and zoledronic acid inception cohorts | — | Completed | — | Osteonecrosis of the Jaw, Infection Leading to Hospitalization | 2,560 | 2019-08-05actual | — | 2023-06-22 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesNCT03465540results2023-04-12Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Strategic decisions | Drug: AMG 397, Dexamethasone, Azacitidine | Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL | 24 | 2019-07-25actual | — | 2023-04-12 |
| Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)NCT02393859results2020-07-13Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Blinatumomab, Dexamethasone, Vincrisitne, Daunorubicin, Methotrexate, Ifosfamide, PEG-asparaginase, Erwinia-asparaginase | Leukemia, Acute Lymphoblastic | 111 | 2019-07-17actual | — | 2026-06-26 |
| Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.NCT03158688results2020-09-11Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dexamethasone, Daratumumab, Carfilzomib | Relapsed Multiple Myeloma, Refractory Multiple Myeloma | 466 | 2019-07-14actual | — | 2025-05-09 |
| Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed DyslipidemiaNCT02833844results2020-07-21Percent Change From Baseline in LDL-C at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Evolocumab, Placebo | Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | 467 | 2019-07-09actual | — | 2022-07-22 |
| Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to RituximabNCT02747043results2020-08-18Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of DiseaseRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: ABP 798, Rituximab | Lymphoma, Non-Hodgkin | 256 | 2019-06-28actual | — | 2022-09-10 |
| Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaNCT01832727results2020-07-13Participants With Dose-Limiting Toxicities (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Enrollment halted during phase 2 to reformulate the investigational product | Drug: Oprozomib, Dexamethasone | Multiple Myeloma | 65 | 2019-06-25actual | — | 2020-07-13 |
| Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for MelanomaNCT02211131results2020-05-28Recurrence-Free Survival (RFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Talimogene Laherparepvec · Procedure: Immediate surgical resection of melanoma lesion(s) | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma | 150 | 2019-04-30actual | — | 2023-06-05 |
| A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple MyelomaNCT01999335results2021-04-27Number of Participants With Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ007 was halted during dose-expansion. | Drug: Oprozomib, Pomalidomide, Dexamethasone | Multiple Myeloma | 33 | 2019-04-25actual | — | 2021-04-27 |
| A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.NCT03456856results2020-04-07Change From Baseline in Heart Rate (HR) at Day 57Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Ivabradine | Heart Failure (HF) | 30 | 2019-04-19actual | — | 2021-10-28 |
| Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure PatientsNCT03276728results2022-08-08Participants With Treatment Emergent Adverse Events (TEAE)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Terminated (Decision by the Sponsor. The study was not terminated due to a safety reason.) | Drug: AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV | Heart Failure, Healthy Volunteer | 182 | 2019-04-18actual | — | 2022-08-08 |
| A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for OsteoporosisNCT03432533results2020-04-10Percent Change From Baseline in Lumbar Spine BMD at Month 6Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: romosozumab HCP administration with PFS · Device: romosozumab self-administration with AI/Pen | Post-Menopausal Osteoporosis | 283 | 2019-04-11actual | — | 2020-11-23 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese ParticipantsNCT05885451Maximum Observed Serum Concentration (Cmax) of AMG 592Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: AMG 592 · Other: Placebo | Chronic Graft-versus-Host Disease (cGVHD) | 18 | 2019-04-11actual | — | 2023-06-02 |
| A Phase1 Study of VIB9600NCT03621605Safety and tolerability of single and multiple doses of VIB9600Randomized · Triple-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to tolerability issues. | Biological: VIB9600 · Drug: Placebos | Safety Issues | 24 | 2019-04-08actual | — | 2024-12-13 |
| Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell LymphomaNCT03023878results2020-03-26Participants With Treatment-Emergent (Blinatumomab) Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Blinatumomab, Investigator's Choice Chemotherapy, Dexamethasone | High-risk Diffuse Large B-Cell Lymphoma | 47 | 2019-04-04actual | — | 2020-09-14 |
| Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical StudyNCT03298867results2020-03-10Percentage of Participants Who Were Proptosis Responders at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Teprotumumab · Other: Placebo | Thyroid Eye Disease, Graves' Orbitopathy | 83 | 2019-02-13actual | — | 2024-07-11 |
| Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaNCT02412306results2020-01-10Phase 1b: Number of Participants With Dose-limiting ToxicitiesNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Blinatumomab | Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia | 66 | 2019-02-06actual | — | 2022-12-12 |
| A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416NCT03283098results2020-02-10Pharmacokinetic (PK) Parameter: Time to Maximum Drug Concentration (Tmax) of Plasma Etelcalcetide on Days 1 and 27Randomized · Triple-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 1 | Completed | Drug: Etelcalcetide, Placebo | Secondary Hyperparathyroidism | 33 | 2019-02-04actual | — | 2020-02-10 |
| A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in BelgiumNCT03096990observationalProportion of patients showing response assessed by improvement for at least 2 out of 4 measures which compose the Psoriatic Arthritis Response Criteria (PsARC) at 6 months after apremilast initiation with respect to baseline | — | Completed | Drug: apremilast | Arthritis, Psoriatic | 106 | 2018-12-27actual | — | 2020-04-29 |
| A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in BelgiumNCT03097003observationalProportion of patients with Patient Benefit Index for skin diseases (standard version) (PBI-S) ≥ 1 at 6 months after apremilast initiation. | — | Completed | Drug: Apremilast | Psoriasis | 124 | 2018-12-20actual | — | 2020-04-27 |
| A Phase 1 Study in Subjects With Relapsed or Refractory Multiple MyelomaNCT02561962results2021-10-07Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 224 | Multiple Myeloma | 42 | 2018-11-30actual | — | 2024-02-01 |
| Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaNCT03029234results2019-11-21Overall Response Rate (ORR) After at Least 6 Cycles of Treatment Assessed by the Independent Review CommitteeOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dexamethasone, Carfilzomib | Relapsed and Refractory Multiple Myeloma | 126 | 2018-11-05actual | — | 2022-05-25 |
| A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving HaemodialysisNCT02833857results2019-07-10Common Treatment-emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Etelcalcetide | Chronic Kidney Disease, Secondary Hyperparathyroidism | 11 | 2018-10-31actual | — | 2019-07-10 |
| Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine PreventionNCT03238781results2020-02-07Change From Baseline in Monthly Migraine Days to the Last 4 Weeks of the 12 Week Double-Blind Treatment PeriodRandomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, AMG 301 | Chronic Migraine or Episodic Migraine | 343 | 2018-10-16actual | — | 2020-02-07 |
| Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to RituximabNCT02792699results2019-10-23Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) After the Second Infusion of the First DoseRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ABP 798, Rituximab (US), Rituximab (EU) | Arthritis, Rheumatoid | 311 | 2018-10-08actual | — | 2020-10-06 |
| A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic ImpairmentNCT06004934Maximum Plasma Concentration (Cmax) of AvacopanNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Avacopan | Hepatic Impairment | 24 | 2018-09-18actual | — | 2023-08-22 |
| Single Ascending Dose Study of AMG 570 in Healthy SubjectsNCT02618967results2021-10-15Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: AMG 570, AMG 570 Matching Placebo | Systemic Lupus Erythematosus | 56 | 2018-09-06actual | — | 2024-05-14 |
| Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)NCT02279173results2019-08-28Percentage of Time With a Platelet Response During the First 6 Months of TreatmentOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Romiplostim | Immune Thrombocytopenia | 203 | 2018-08-30actual | — | 2022-06-23 |
| A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the ScalpNCT03123471results2019-09-04Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From BaselineRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Apremilast · Other: Placebo | Psoriasis | 303 | 2018-08-13actual | — | 2020-05-13 |
| Open-Label Access Protocol of Denosumab for Subjects With Advanced CancerNCT01419717results2019-09-09Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Denosumab | Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer | 129 | 2018-08-10actual | — | 2019-09-24 |
| Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORRNCT02322736observationalTo describe the pattern of use of Vectibix® in combination with chemotherapy in 1st line or in 2nd line mCRC treatments as per approved Vectibix® indication. | — | Completed | — | Metastatic Colorectal Cancer | 218 | 2018-08-03actual | — | 2019-11-13 |
| Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice ConditionsNCT03106051observationalPercentage of patients with an improvement of ≥ 1 points on the Physician's Global Assessment (PGA) scale on visit 3 compared to baseline on the Physician's Global Assessment scale (PGA; scale from 0-4) | — | Completed | — | Arthritis, Psoriatic | 526 | 2018-07-31actual | — | 2025-09-03 |
| Open Label Study of Long Term Evaluation Against LDL-C TrialNCT01439880results2019-07-10Number of Participants With Adverse EventsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Evolocumab · Other: Standard of care | Hypercholesterolemia | 1,324 | 2018-06-20actual | — | 2022-09-21 |
| A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal CancerNCT05913115Number of Participants who Experience Grade 3 or Grade 4 Dose-limiting Toxicities (DLTs)Open-label · Basic science | Phase 1 | Completed | Drug: FPA144 | Gastric or Gastroesophageal Cancer | 6 | 2018-06-19actual | — | 2023-06-22 |
| Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed DyslipidemiaNCT01854918results2019-06-11Number of Participants With Adverse EventsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Evolocumab · Drug: Standard of Care | Hyperlipidemia and Mixed Dyslipidemia | 3,681 | 2018-05-31actual | — | 2019-06-11 |
| A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid ArthritisNCT02780388results2019-09-16Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: VIB4920 · Other: Placebo | Adult Onset Rheumatoid Arthritis | 57 | 2018-05-21actual | — | 2024-12-27 |
| Study of Denosumab in Subjects With Giant Cell Tumor of BoneNCT00680992results2018-12-10Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Denosumab | Cancer, Giant Cell Tumors, Giant Cell Tumor of Bone, Benign Giant Cell Tumors | 535 | 2018-05-17actual | — | 2022-09-22 |
| Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL DisordersNCT01624142results2019-01-28Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Biological: Evolocumab | Severe Familial Hypercholesterolemia | 300 | 2018-05-11actual | — | 2024-05-28 |
| Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to InfliximabNCT02937701results2019-08-28Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: ABP 710, Infliximab | Arthritis, Rheumatoid | 558 | 2018-04-16actual | — | 2019-08-28 |
| Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))NCT02729025results2019-04-23Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Evolocumab, Placebo | Subjects With Hyperlipidemia, Dyslipidemia | 129 | 2018-04-05actual | — | 2022-09-23 |
| Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal FunctionNCT03318809results2021-01-27AMG 986 Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 986 | Heart Failure | 12 | 2018-03-12actual | — | 2022-06-23 |
| Open-label Extension (OLE) Study to Assess Safety and Efficacy of EvolocumabNCT02304484results2019-03-19Number of Participants With Adverse EventsOpen-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 3 | Completed | Biological: Evolocumab | Hypercholesterolemia | 770 | 2018-03-09actual | — | 2019-03-19 |
| A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With OsteoporosisNCT02791516results2019-07-05Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar SpineRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Romosozumab, Placebo | Postmenopausal Osteoporosis | 67 | 2018-02-12actual | — | 2019-10-07 |
| A Study of CCX168 in Japanese and Caucasian Healthy Adult MalesNCT05988008Number of Participants Experiencing Adverse EventsRandomized · Single-masked · Basic science | Phase 1 | Completed | Drug: CCX168, Placebo | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 80 | 2018-01-26actual | — | 2023-08-14 |
| Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic ArthritisNCT02376790results2019-02-22Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Etanercept, Methotrexate, Placebo to Etanercept, Placebo to Methotrexate | Psoriatic Arthritis | 851 | 2018-01-09actual | — | 2022-09-21 |
| Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip ReplacementNCT02576652results2019-04-26Percentage of Participants With Modeling Based Bone Formation in the Femoral NeckOpen-label · Basic scienceStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 4 | Completed | Other: Tetracycline, Demeclocycline · Procedure: Total Hip Replacement | Osteoporosis | 6 | 2017-12-18actual | — | 2019-04-26 |
| Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed DyslipidemiaNCT02662569results2019-01-11Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Evolocumab · Drug: Atorvastatin · Other: Placebo | Diabetes, Hyperlipidemia, Mixed Dyslipidemia | 986 | 2017-12-06actual | — | 2019-01-11 |
| AMG 529 First in Human StudyNCT03170193results2019-07-05Number of Participants With Adverse Events (AEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: AMG 529, Placebo | Cardiovascular | 48 | 2017-11-17actual | — | 2019-07-05 |
| A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal CancerNCT02291614results2021-02-24Number of Participants With Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: The study was terminated because of immunogenicity and business decision. | Drug: AMG 211 | GI Adenocarcinoma | 45 | 2017-11-06actual | — | 2021-03-16 |
| Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)NCT02626000results2019-06-10Number of Participants With a Dose Limiting Toxicity (DLT)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Talimogene Laherparepvec · Biological: Pembrolizumab | Carcinoma of the Head and Neck | 36 | 2017-11-02actual | — | 2021-09-08 |
| Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in FranceNCT02347865observationalpatient occurence of persistence (persistence is defined in the outcome description) at 12 months | — | Completed | Drug: AMG 162 - Prolia, AMG 162 - Prolia | Post Menopausal Osteoporosis | 777 | 2017-10-26actual | — | 2022-11-14 |
| A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune DiseasesNCT02780674Incidence of Treatment-Emergent Adverse EventRandomized · Double-masked · Treatment | Phase 1 | Completed | Biological: MEDI7734, Placebo | Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc | 36 | 2017-10-23actual | — | 2024-12-13 |
| Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney DiseaseNCT01652872results2018-11-08Percentage of Participants in Receipt of 1 or More RBC TransfusionsRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Darbepoetin alfa · Other: Placebo | Anemia in Chronic Kidney Disease Patients Not on Dialysis | 756 | 2017-10-19actual | — | 2022-09-21 |
| To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine PatientsNCT02542605results2019-06-03Number of Participants With a MLA Within 24 Hours of Challenge Agent InfusionRandomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Erenumab, Placebo, PACAP-38 Challenge Agent | Migraine | 35 | 2017-09-28actual | — | 2019-06-03 |
| Efficacy and Safety Study of Apremilast to Treat Active Ulcerative ColitisNCT02289417results2018-10-29Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12Randomized · Quadruple-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Completed | Drug: Apremilast, Placebo | Ulcerative Colitis | 170 | 2017-09-25actual | — | 2020-05-07 |
| A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's DiseaseNCT02307513results2019-09-11Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Apremilast, Placebo | Behçet's Syndrome | 207 | 2017-09-25actual | — | 2021-07-22 |
| A Safety and Efficacy Study to Evaluate AMG 334 in Migraine PreventionNCT02630459results2019-03-13Change From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, Erenumab, Erenumab | Migraine | 475 | 2017-09-25actual | — | 2022-10-12 |
| Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic ArthritisNCT02986139results2018-10-31Injection Site PainRandomized · Quadruple-masked · Supportive careStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Commercial Formulation Etanercept, New Formulation Etanercept | Arthritis, Rheumatoid; Arthritis, Psoriatic | 111 | 2017-09-08actual | — | 2019-07-18 |
| A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque PsoriasisNCT02576678results2018-09-27Number of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Apremilast | Psoriasis | 42 | 2017-09-04actual | — | 2020-05-07 |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)NCT01077154results2018-10-03Bone Metastasis-free Survival (BMFS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: SAP 3.0 ↗ · Statistical Analysis Plan: SAP 3.0 Addendum ↗ | Phase 3 | Terminatedsponsor's stated reason: Terminated: Amgen decision following Primary Analysis. Not due to safety reason | Drug: Placebo, Denosumab | Breast Cancer | 4,509 | 2017-08-31actual | — | 2021-09-28 |
| Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With ApremilastNCT02749370results2018-08-27Percentage of Participants With a PASI 75 Response at Week 12Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Etanercept | Plaque Psoriasis | 80 | 2017-08-14actual | — | 2020-05-13 |
| Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4NCT02634580results2018-08-31Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Evolocumab · Drug: Ezetimibe, Placebo to Evolocumab, Placebo Ezetimibe | Hypercholesterolemia | 61 | 2017-08-10actual | — | 2020-11-10 |
| Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed DyslipidemiaNCT02739984results2018-08-31Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Evolocumab · Drug: Placebo to Evolocumab | Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes | 424 | 2017-08-03actual | — | 2018-08-31 |
| Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)NCT01197378results2018-07-24Number of Participants With Treatment-emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Cysteamine Bitartrate Delayed-release Capsules | Cystinosis | 60 | 2017-06-26actual | — | 2024-12-27 |
| Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected MelanomaNCT02366195results2018-07-18Odds Ratio of Baseline Intratumoral CD8+ Cell Density and Objective Response RateOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Talimogene Laherparepvec | Unresected Stage IIIb to IVM1c Melanoma | 112 | 2017-06-26actual | — | 2021-11-30 |
| A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy ParticipantsNCT05873907Number of Participants with Treatment-emergent Adverse Events (TEAEs)Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: AMG 592 · Other: Placebo | Chronic Graft-versus-host Disease (cGVHD) | 64 | 2017-06-16actual | — | 2023-05-24 |
| Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple MyelomaNCT02412878results2018-12-13Progression Free SurvivalRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Carfilzomib, Dexamethasone | Multiple Myeloma | 478 | 2017-06-15actual | — | 2022-09-23 |
| A Study of Otezla® in Patients With Plaque Psoriasis Under Routine ConditionsNCT02626793observationalChange from baseline in the Dermatology Life Quality Index (DLQI) ≤ 5 or improvement in DLQI by ≥ 5 points at Visit 2 from baseline | — | Completed | — | Psoriasis | 391 | 2017-06-08actual | — | 2022-02-08 |
| Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyNCT00858364results2018-07-06Overall Survival (OS)Randomized · Quadruple-masked · Supportive careStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminated | Drug: Darbepoetin alfa, Placebo | Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer | 2,549 | 2017-06-07actual | — | 2022-11-30 |
| A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.NCT02174861results2018-06-19Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Erenumab | Treatment for Prevention of Chronic Migraine | 609 | 2017-05-26actual | — | 2022-10-12 |
| A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment ProtocolsNCT00884312results2018-05-14Number of Participants With Peripheral NeuropathyOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Carfilzomib | Multiple Myeloma, Solid Tumors | 101 | 2017-05-17actual | — | 2018-05-14 |
| Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac DiseaseNCT02633020results2019-12-27Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial LymphocytesRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: AMG 714, Placebo | Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma | 28 | 2017-04-11actual | — | 2019-12-27 |
| Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's AtaxiaNCT02797080results2018-05-01Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: interferon γ-1b | Friedreich's Ataxia | 38 | 2017-03-31actual | — | 2024-12-10 |
| Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia StudyNCT02593773results2018-05-18Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Interferon γ-1b | Friedreich's Ataxia | 86 | 2017-03-21actual | — | 2024-12-19 |
| Darbepoetin Alfa MDS Companion ProtocolNCT02175277results2018-10-11Number of Participants With Treatment-emergent Adverse EventsOpen-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 3 | Completed | Drug: Darbepoetin Alfa | Myelodysplastic Syndrome (MDS) | 9 | 2017-03-20actual | — | 2018-11-14 |
| Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on DialysisNCT02341417results2018-05-18Number of Participants With Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Cinacalcet | Secondary Hyperparathyroidism, Chronic Kidney Disease | 28 | 2017-03-15actual | — | 2020-06-29 |
| A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial DiseaseNCT02473445results2018-05-11Change in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) ScoreOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001. | Drug: Cysteamine Bitartrate | Mitochondrial Diseases | 22 | 2017-03-06actual | — | 2024-12-27 |
| Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With OsteoporosisNCT01631214results2018-12-12Percentage of Participants With New Vertebral Fractures Through Month 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Romosozumab · Drug: Alendronate, Placebo to Romosozumab, Placebo to Alendronate | Postmenopausal Women With Osteoporosis | 4,093 | 2017-02-27actual | — | 2025-02-21 |
| To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)NCT01257737results2018-05-04Number of Participants With at Least One Adverse EventOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: HPN-100 | Urea Cycle Disorders | 88 | 2017-02-16actual | — | 2024-08-22 |
| A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac DiseaseNCT02637141results2019-12-03Percent Change From Baseline in Villous Height to Crypt Depth Ratio (VH:CD) at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: AMG 714, Placebo · Other: Placebo Gluten Challenge, Gluten Challenge | Celiac Disease | 64 | 2017-02-15actual | — | 2019-12-03 |
| Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)NCT02575833results2018-07-05Change From Baseline in Total Exercise TimeRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Erenumab, Placebo | Stable Angina | 89 | 2017-01-23actual | — | 2018-08-24 |
| A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia PurpuraNCT01071954results2019-01-29Number of Participants With Adverse EventsOpen-label · Supportive care | Phase 3 | Completed | Biological: Romiplostim | Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP | 66 | 2017-01-12actual | — | 2020-01-18 |
| Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With CystinosisNCT01744782results2018-01-16Mean White Blood Cell (WBC) Cystine Concentration at Each VisitOpen-label · Treatment | Phase 3 | Completed | Drug: RP103 | Cystinosis | 17 | 2016-12-13actual | — | 2024-12-27 |
| Safety Study of AMG 228 to Treat Solid TumorsNCT02437916Subject incidence of dose limiting toxicities (DLT)Open-label · Treatment | Phase 1 | Terminated | Drug: AMG 228 | Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Transitional Cell Carinoma of Bladder, Colorectal Cancer | 30 | 2016-12-12actual | — | 2022-11-08 |
| Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney DiseaseNCT01428154Number of subjects with clinically significant changes in physical examinations, laboratory safety tests, and vital signsOpen-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Difficulty in recruitment. PDCO in the Day 30 summary report agrred to remove the PK study in children \<1 year of age. | Drug: Darbepoetin alfa | Anemia, Chronic Kidney Disease | 0 | Nov 2016 | — | 2016-06-17 |
| Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer PatientsNCT01732783results2018-08-20observationalTotal Number of Panitumumab Infusions | — | Completed | Other: Panitumumab + Chemotherapy | Wild-type RAS Metastatic Colorectal Cancer | 213 | 2016-11-30actual | — | 2022-11-08 |
| Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's AtaxiaNCT02415127results2017-12-08Change From Baseline to Week 26 in the Friedreich's Ataxia Rating Scale (FARS)-mNeuro ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Interferon γ-1b, Placebo | Friedreich's Ataxia | 92 | Nov 2016actual | — | 2024-12-19 |
| A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy AdultsNCT02777554results2021-07-22Part 1: Peak Maximum Plasma Concentration (Cmax) of ApremilastRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Apremilast IR, Apremilast XL | Healthy Volunteers | 144 | 2016-11-22actual | — | 2021-07-22 |
| Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated RiskNCT01764633results2018-02-15Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary RevascularizationRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Evolocumab · Drug: Placebo | Dyslipidemia | 27,564 | 2016-11-11actual | — | 2024-05-28 |
| Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk SubjectsNCT02207634results2018-01-16Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z ScoreRandomized · Quadruple-masked · Other | Phase 3 | Completed | Biological: Evolocumab · Drug: Placebo, Background Statin Therapy | Dyslipidemia | 1,974 | 2016-11-11actual | — | 2018-01-16 |
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on HemodialysisNCT02102204results2017-11-17Number of Participants With Adverse EventsOpen-label · Treatment | Phase 3 | Completed | Drug: Etelcalcetide | Hyperparathyroidism, Secondary | 902 | 2016-11-04actual | — | 2017-11-17 |
| Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid TumorsNCT02016534Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Amgen decision following interim review of efficacy and safety data from the AMG 337 program. | Drug: AMG 337 | Stomach Neoplasms | 60 | Oct 2016actual | — | 2017-07-02 |
| Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial DiseaseNCT02023866results2017-11-13Change From Baseline in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Sections I-IVOpen-label · Treatment | Phase 2 | Completed | Drug: Cysteamine Bitartrate | Inherited Mitochondrial Disease, Including Leigh Syndrome | 36 | Oct 2016actual | — | 2024-12-27 |
| Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk ChemotherapyNCT02178475results2018-07-23observationalPercentage of Participants With Febrile Neutropenia | — | Completed | — | Chemotherapy-induced Febrile Neutropenia | 943 | 2016-10-28actual | — | 2018-07-23 |
| A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle DisordersNCT02246218results2019-03-05Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 2 Months to <2 Years ParticipantsOpen-label · Treatment | Phase 4 | Completed | Drug: RAVICTI | Urea Cycle Disorder | 27 | 2016-10-17actual | — | 2024-07-01 |
| Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy FemalesNCT02792517results2018-12-20Maximum Observed Plasma Concentration (Cmax) of Ethinyl EstradiolOpen-label · Basic science | Phase 1 | Completed | Drug: Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive | Headache, Migraine | 41 | 2016-09-09actual | — | 2018-12-20 |
| Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine PreventionNCT02456740results2018-07-10Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment PeriodRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Erenumab, Placebo | Migraine | 955 | 2016-09-05actual | — | 2022-10-12 |
| Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study EnrollmentNCT02585895results2017-09-19Percentage of Participants With Apheresis Avoidance at the End of Randomized TherapyRandomized · Open-label · Treatment | Phase 3 | Completed | Biological: Evolocumab · Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis | Hypercholesterolemia | 39 | 2016-09-01actual | — | 2022-11-30 |
| Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung CancerNCT01987232results2017-08-28Number of Participants With Dose-limiting ToxicitiesOpen-label · Treatment | Phase 1/2 | Completed | Drug: Carfilzomib, Carboplatin, Etoposide | Extensive-Stage Small-Cell Lung Cancer | 32 | Aug 2016actual | — | 2017-08-28 |
| A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)NCT02103283Safety of RV001in subjects with Diabetic Macular EdemaOpen-label · Treatment | Phase 1 | Completed | Drug: Teprotumumab | Diabetic Macular Edema | 5 | Aug 2016actual | — | 2025-06-25 |
| Ipilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaNCT01740297results2017-10-09Phase 1b: Number of Participants With Dose-limiting ToxicitiesRandomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Talimogene laherparepvec, Ipilimumab | Melanoma | 217 | 2016-08-23actual | — | 2024-05-14 |
| Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous SumatriptanNCT02741310results2019-03-05Time-weighted Averages of Mean Arterial PressureRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Placebo, Sumatriptan, Erenumab | Healthy Subjects | 34 | 2016-08-11actual | — | 2019-04-02 |
| Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic MalignanciesNCT01416428Determine the MTD (Phase 1) and ORR (Phase 2).Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted. | Drug: oprozomib | Multiple Myeloma, Waldenstrom Macroglobulinemia | 210 | 2016-08-08actual | — | 2022-11-08 |
| Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean SubjectsNCT02802735results2021-07-06Part 1: Maximum Observed Plasma Concentration (Cmax) of ApremilastRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Apremilast, Placebo | Pharmacokinetics | 28 | 2016-08-05actual | — | 2021-07-06 |
| Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung CancerNCT01951586results2017-08-28Overall Survival (OS)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid | Non-Small Cell Lung Cancer | 226 | 2016-07-29actual | — | 2021-10-25 |
| A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple MyelomaNCT01677858results2017-08-09Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)Open-label · Treatment | Phase 1/2 | Completed | Drug: Carfilzomib, Dexamethasone | Multiple Myeloma | 116 | 2016-07-22actual | — | 2022-09-23 |
| Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaNCT01345019results2018-03-07Time to First On-study Skeletal Related EventRandomized · Quadruple-masked · Supportive care | Phase 3 | Completed | Drug: Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase) | Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions | 1,718 | 2016-07-19actual | — | 2022-11-08 |
| Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaNCT01818752results2017-08-01Progression-Free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Carfilzomib, Bortezomib, Melphalan, Prednisone | Multiple Myeloma | 955 | 2016-07-15actual | — | 2019-08-26 |
| GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular UltrasoundNCT01813422results2018-01-04Change From Baseline in Percent Atheroma Volume at Week 78Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Evolocumab · Drug: Placebo | Hypercholesterolemia | 970 | 2016-07-12actual | — | 2019-02-20 |
| Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine PreventionNCT02483585results2018-06-25Change From Baseline in Monthly Migraine Days at Week 12Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Erenumab, Placebo | Migraine | 577 | 2016-07-11actual | — | 2022-10-12 |
| Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on DialysisNCT02138838results2017-09-14Percentage of Participants Who Achieved a ≥ 30% Reduction From Baseline In Mean Plasma iPTH During Weeks 11 to 15Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study. | Drug: Cinacalcet HCl · Dietary supplement: Standard of Care | Chronic Kidney Disease, Secondary Hyperparathyroidism | 55 | 2016-06-23actual | — | 2020-06-29 |
| Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking GlucocorticoidsNCT01575873results2018-07-27Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | 795 | 2016-06-21actual | — | 2018-07-27 |
| Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary HyperparathyroidismNCT01439867results2017-08-11Percentage of Participants With HypocalcemiaOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study. | Drug: Cinacalcet hydrochloride, Standard of Care | Chronic Kidney Disease, Hyperparathyroidism, Secondary | 18 | 2016-06-03actual | — | 2020-06-17 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal PolypsNCT02170337Safety and tolerabilityRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: AMG 282, Placebo | Chronic Rhinosinusitis With Nasal Polyps | 41 | May 2016actual | — | 2016-06-01 |
| Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone LossNCT00925600results2017-05-30Percentage of Participants With Lens Opacification Event Development or Progression by Month 12Randomized · Quadruple-masked · Supportive care | Phase 3 | Completed | Biological: Denosumab, Placebo | Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer | 769 | 2016-05-12actual | — | 2017-05-30 |
| Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast CancerNCT01901146results2019-08-07Percentage of Participants With a Pathologic Complete ResponseRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: ABP 980, Trastuzumab, Paclitaxel · Procedure: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection | Breast Cancer | 725 | 2016-05-05actual | — | 2019-08-07 |
| AMG 595 First-in-Human in Recurrent GliomasNCT01475006Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: AMG 595 | Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme | 32 | Apr 2016actual | — | 2016-04-15 |
| Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid ArthritisNCT02114931results2017-04-24Number of Participants With Adverse EventsOpen-label · Treatment | Phase 3 | Completed | Biological: ABP 501 | Arthritis, Rheumatoid | 467 | Apr 2016actual | — | 2017-04-24 |
| Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving HemodialysisNCT02253654results2017-05-12Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation PeriodRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Epoetin alfa | Renal Insufficiency, Chronic, Anemia, Renal Dialysis, Erythrocyte Transfusion | 216 | 2016-04-27actual | — | 2017-05-19 |
| Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated VasculitisNCT02222155results2023-08-16Incidence of Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids · Other: Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids | ANCA-associated Vasculitis | 42 | 2016-04-24actual | — | 2025-03-13 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian CancerNCT01493505Progression free survivalRandomized · Triple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Amgen Administrative Decision - termination of LTFU | Drug: AMG 386, Paclitaxel, AMG 386 Placebo, Carboplatin | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer | 1,015 | Mar 2016actual | — | 2017-02-23 |
| Safety Study of AMG 557 in Subjects With Lupus ArthritisNCT01683695Treatment-emergent adverse events, vital signs, physical examinations, clinical laboratory tests, ECGs, and the incidence of binding and neutralizing antibodies to AMG 557.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: AMG 557, Matching Placebo | Lupus Arthritis, Systemic Lupus Erythematosus | 20 | Mar 2016actual | — | 2017-01-24 |
| Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye DiseaseNCT01868997results2017-08-30Responder Status at Week 24Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: teprotumumab, normal saline | Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy | 88 | Mar 2016actual | — | 2024-12-17 |
| A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.NCT01928368Incidence of treatment emergent adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AMG 282, AMG 282 Matching Placebo | Asthma | 70 | Mar 2016actual | — | 2016-12-14 |
| A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma SubjectsNCT01980589results2016-10-31Number of Participants With Dose-limiting Toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: Carfilzomib, Cyclophosphamide, Dexamethasone | Multiple Myeloma | 22 | Mar 2016actual | — | 2017-05-30 |
| A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant MedicationsNCT06004947Cohort A: Maximum Plasma Concentration (Cmax) of MidazolamNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 32 | 2016-03-15actual | — | 2023-08-22 |
| Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid ArthritisNCT02499315The number of subjects reporting of treatment-emergent adverse events or clinically significant changes in physical examinations, vital signs, laboratory safety tests, and ECGsRandomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study has stopped due to a decision by Amgen to terminate the program | Drug: AMG 357, Placebo | Rheumatoid Arthritis | 32 | Feb 2016actual | — | 2016-05-06 |
| Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or SchizoaffectiveNCT02504476Reported treatment-emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: AMG 581, Placebo, Midazolam | Schizophrenia or Schizoaffective Disorder | 52 | Feb 2016actual | — | 2016-03-07 |
| Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral SuspensionNCT02641353results2021-08-05Maximum Observed Plasma Concentration (Cmax) of ApremilastRandomized · Open-label · Other | Phase 1 | Completed | Drug: Apremilast Tablet, Apremilast Oral Suspension | Healthy Volunteers | 34 | 2016-02-27actual | — | 2021-08-05 |
| A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine PreventionNCT02066415results2018-06-21Change From Baseline in Monthly Migraine DaysRandomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: Erenumab · Drug: Placebo | Treatment for Prevention of Chronic Migraine | 667 | 2016-02-24actual | — | 2022-10-12 |
| A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With OsteoporosisNCT02186171results2019-05-28Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12Randomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: Romosozumab · Drug: Placebo | Osteoporosis in Men | 245 | 2016-02-15actual | — | 2019-05-28 |
| A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.NCT02425826results2017-06-06Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Apremilast, Placebo, Placebo-Apremilast | Parapsoriasis | 221 | 2016-02-12actual | — | 2023-06-05 |
| A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168NCT05988021Maximum Plasma Concentration (Cmax) of CCX168Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: CCX168 | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 16 | 2016-02-09actual | — | 2023-08-14 |
| Effects of Denosumab on the Pharmacokinetics of EtanerceptNCT01294397results2017-06-20Area Under the Serum Concentration-time Curve From 0 to 168 Hours (AUC0-168) for EtanerceptOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Lack of enrollment. | Drug: Etanercept, Denosumab | Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis | 19 | Jan 2016actual | — | 2017-06-20 |
| Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene LaherparepvecNCT02014441results2017-02-14Percentage of Participants With Detectable Talimogene Laherparepvec Deoxyribonucleic Acid (DNA) During the First Three CyclesOpen-label · Treatment | Phase 2 | Completed | Drug: Talimogene laherparepvec | Melanoma | 61 | 2016-01-25actual | — | 2019-11-20 |
| Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)NCT02013167results2017-08-09Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Terminated | Drug: Blinatumomab, Standard of Care Chemotherapy | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | 405 | 2015-12-29actual | — | 2024-03-05 |
| Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With OsteoporosisNCT01575834results2018-11-08Percentage of Participants With New Vertebral Fracture Through Month 12Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Romosozumab, Placebo, Denosumab | Postmenopausal Osteoporosis | 7,180 | 2015-12-14actual | — | 2024-08-28 |
| Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese ParticipantsNCT05995691AUCinf of ABP 501Randomized · Single-masked · Basic science | Phase 1 | Completed | Drug: ABP 501, Adalimumab | Healthy Volunteers | 179 | 2015-12-04actual | — | 2023-08-16 |
| Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung CancerNCT01666977Progression Free SurvivalRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: AMG 386, AMG 386, AMG 386 Placebo, Pemetrexed, Carboplatin | Non Small Cell Lung Cancer | 36 | Nov 2015actual | — | 2016-06-03 |
| Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration TrainingNCT02085993observationalSuccessful self administration of romiplostim | — | Completed | — | Immune Thrombocytopenic Purpura | 41 | Nov 2015actual | — | 2015-12-22 |
| Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque PsoriasisNCT02274792results2016-12-29Percentage of Participants With Positive Anti-etanercept Binding Antibody Response During the StudyOpen-label · Treatment | Phase 4 | Completed | Drug: Etanercept | Plaque Psoriasis | 132 | Nov 2015actual | — | 2016-12-29 |
| Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3NCT01984424results2018-03-13Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Atorvastatin, Placebo to Atorvastatin, Ezetimibe, Evolocumab · Other: Placebo to Ezetimibe, Placebo to Evolocumab | Hyperlipidemia | 511 | 2015-11-10actual | — | 2018-11-29 |
| A Phase 1/2 Study Evaluating AMG 337 in Asian SubjectsNCT02096666Phase 1- Adverse events and clinical laboratory abnormalitiesOpen-label · Treatment | Phase 1/2 | Completed | Drug: AMG 337 | Stomach Neoplasms | 11 | 2015-11-05actual | — | 2021-12-28 |
| A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated VasculitisNCT01363388results2020-07-27Proportion of Subjects Achieving Disease Response at Day 85Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, CCX168 | Vasculitis | 67 | Oct 2015actual | — | 2025-03-13 |
| Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic DermatitisNCT02087943results2016-12-12Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Apremilast, Apremilast, Placebo, Placebo | Dermatitis, Atopic Dermatitis | 191 | Oct 2015actual | — | 2020-05-07 |
| A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid ArthritisNCT02287610results2017-02-03observationalMean Change in Severity of Morning Stiffness (Using 100mm VAS) From Baseline (Week 0) to Final Follow-Up Visit | — | Completed | Drug: RAYOS (delayed-release prednisone) | Rheumatoid Arthritis | 75 | Oct 2015actual | — | 2024-12-18 |
| Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid ArthritisNCT02346877results2017-03-27Persistence of Study Drug Measured at 52 WeeksNon-randomized · Open-label · Diagnostic | Phase 4 | Terminatedsponsor's stated reason: Business Decision | Behavioral: Personalized Patient Counselling | Persistence to Enbrel | 19 | Oct 2015actual | — | 2017-03-27 |
| Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581NCT02567370Reported treatment-emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: AMG 581, Placebo | Schizophrenia or Schizoaffective Disorder | 70 | Oct 2015actual | — | 2015-10-23 |
| A Study of AMG 337 in Subjects With Advanced Solid TumorsNCT01253707To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.Open-label · Treatment | Phase 1 | Completed | Drug: AMG 337 | Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors | 111 | 2015-10-01actual | — | 2022-11-07 |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney DiseaseNCT01290029results2016-12-19Number of Participants With Adverse EventsOpen-label · Treatment | Phase 1 | Completed | Drug: Cinacalcet | Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism | 14 | 2015-09-23actual | — | 2020-06-17 |
| Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS BlockadeNCT02384317results2023-08-01Change in Slope of First Morning Urinary PCR From the 8-week RAAS Blocker run-in Period to the 12-week CCX168 Treatment PeriodOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CCX168 | Immunoglobulin A Nephropathy | 7 | 2015-09-13actual | — | 2025-03-13 |
| Observational Study of Denosumab (Prolia®) in Postmenopausal Women With OsteoporosisNCT01668589results2016-09-20observationalPercentage of Participants Persistent With Denosumab Injections at 12 Months and 24 Months | — | Completed | — | Postmenopausal Osteoporosis | 1,501 | 2015-08-31actual | — | 2018-01-30 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19